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An adverse drug event (ADE) for this thesis is defined as harm from a medication resulting in 
hospitalisation. Oral anticoagulants are among the most common drugs worldwide which 
contribute to medication-related ADEs. These oral anticoagulants include the non-vitamin K 
antagonist oral anticoagulant (NOACs) and warfarin, a vitamin K antagonist. According to the 
evidence, there are conflicting studies which have cited significant and non-significant 
differences between NOACs and warfarin, with regard to ADEs, including haemorrhage, 
ischaemic stroke and venous thromboembolism (VTE). The majority of these studies have been 
clinical trials and do not include post-marketing surveillance. This thesis compares population-
adjusted rates and risk of ADEs for NOACs (apixaban and rivaroxaban) and warfarin for a 
cohort of patients residing in the Illawarra Shoalhaven region of NSW. In addition, this study 





There are two studies within this thesis. The first study was a retrospective observational cohort 
study of residents within the Illawarra Shoalhaven Local Health District prescribed oral 
anticoagulants between July 1st 2015 and June 30th 2017. This study utilised Pharmaceutical 
Benefits Scheme (PBS) aggregate data and unit record hospitalisation data using ICD-10 AM 
(9th edition) and SNOMED codes for haemorrhage, VTE and ischaemic stroke, for persons 
taking NOACs (apixaban or rivaroxaban) or warfarin. Statistical analysis included modelling 
relative risk and logistic regression to calculate adjusted odds ratios for ADEs requiring 
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hospitalisation among individuals taking NOACs compared to warfarin, accounting for sex, age 
and geographic region. Further contributing factors investigated included renal function, 
comorbidities and thrombophilia. The second study was a small prospective pilot study which 
explored knowledge about anticoagulants, using the Medication Knowledge Tool, and 
medication adherence, using the Morisky Medication Adherence Questionnaire, among vascular 




In 585 of 9,432 hospitalisations for an ADE (haemorrhage, VTE or ischaemic stroke), the 
individual was taking an oral anticoagulant. An analysis of these 585 hospitalisations found, 
when compared to those taking warfarin, individuals taking a NOAC had less risk of 
hospitalisation for an ADE (aOR 0.71, 95% CI 0.60-0.85), including approximately half the risk 
of being hospitalised for an ischaemic stroke ADE (aOR 0.51, 95% CI 0.34-0.78). Specifically, 
when compared to warfarin, individuals taking apixaban had less risk of a total haemorrhagic 
ADE (aOR 0.46, 95% CI 0.34-0.62), lower rates of hospitalisation for clinically relevant non-
major bleeding events (7.7 per 1,000 prescribed per year vs 14.0 per 1,000 prescribed per year), 
and lower risk of a major haemorrhagic event (2.3 per 1,000 prescribed per year vs 6.0 per 1,000 
prescribed per year). In contrast, compared to warfarin, individuals taking rivaroxaban were 
more than twice as likely to be hospitalised for a VTE ADE (aOR 2.02, 95% CI 1.04-3.92), and 
compared to apixaban, individuals taking rivaroxaban were more than twice as likely to be 
hospitalised for a VTE ADE (aOR 2.78, 95% CI 1.16-6.76). The findings of the retrospective 
observational cohort study also suggest that thrombophilia and renal impairment are potential 
contributing factors for oral anticoagulant-related ADEs resulting in hospitalisation and requires 
further investigation on a much larger scale. 
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The small-scale prospective pilot study recruited nine participants. Knowledge of apixaban or 
rivaroxaban was 58.5%, and only two participants knew the most important side effects of their 
anticoagulants, while only one participant knew that skipping a dose of a NOAC could worsen 
their condition. Medication adherence was found to be medium to high among the nine 
participants. Due to the small number of participants in this study, it was not possible to 




This research suggests the importance to patients, prescribers and the health system, of 
understanding the risks associated with taking oral anticoagulants based on a cohort which 
reflects the realities of comorbid conditions and medication knowledge. This research suggests 
there was a lower overall risk of hospitalisation for ADEs, including major haemorrhage and 
ischaemic stroke, for individuals taking NOACs compared to warfarin. In contrast, individuals 
taking warfarin had a much lower risk of experiencing VTE ADEs, which potentially suggests 
that it is a safer option for the treatment and/or prevention of VTE compared to rivaroxaban. 
Further national population studies are needed to compare the risk of ADEs between NOACs 
and warfarin to confirm and expand on these findings due to limitations in the available data. 
There would then be potential to review current practice guidelines recommending all NOACs 
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DAEN  Database of Adverse Event Notifications 
DVT  deep vein thrombosis 
ED  emergency department 
eMR  electronic medical records 
GI  gastrointestinal 
GP  general practitioner 
Hb  haemoglobin 
ICD-10-AM The International Statistical Classification of Diseases and Related Health 
Problems, Tenth Revision, Australian Modification  
IHIP  Illawarra Health Information Platform 
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INR  International Normalised Ratio 
NOAC  non-vitamin k antagonist oral anticoagulant  
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From the time of their introduction, NOACs have been marketed as a superior and more 
convenient treatment option compared to warfarin, because of their fixed dosing regimens and 
no requirement for routine coagulation monitoring (Connell  & Butera 2015). Figure 1 
illustrates the rapid uptake of NOACs in clinical practice for Non-valvular Atrial Fibrillation 
(NVAF) and decline in warfarin use, since the listing of the NOACs on the PBS in Australia.  
NOACs have promptly been accepted as the preferred treatment choice by many healthcare 
practitioners (Connell  & Butera 2015). Although warfarin remains the most prescribed oral 
anticoagulant, since 2015, Australian patients starting oral anticoagulant therapy for the first 
time have been more likely to be commenced on a NOAC, rather than on warfarin (Department 
of Health. 2016). Furthermore, Australian guidelines now recommend NOACs over warfarin for 
NVAF (Brieger et al. 2018) and clinicians treating VTE are advised to prescribe a factor Xa 
inhibitor as the first choice anticoagulant (Tran et al. 2019). 
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*DUSC and DHS supplied prescriptions (accessed March 2016). Includes private, under co‐payment and actual 
(PBS). 
Figure 1- Number of anticoagulant prescriptions supplied from 2010 to 2015  
 
In addition to being useful treatment and prophylactic medications, oral anticoagulants also 
contribute to the ADE profile in Australia. An adverse event is classified as any harmful event 
which occurs during treatment with a drug, without the necessity to link the event with the action 
of the drug (Simper et al. 2017). An adverse drug event (ADE) is an injury resulting from the use 
of a drug and encompasses adverse drug reactions (ADRs) which include an unintended 
response to a drug at normal dose range, medication errors and overdoses (Piazza et al. 2011). 
An ADE for the purpose of this thesis is defined as an event that caused severe harm to an 
individual from medication use that resulted in an unplanned hospitalisation. 
 
ADEs range is severity from mild, self-resolving events, which may not necessitate an 
intervention and can be managed without hospitalisation (Marsh 2018) to severe events which 
require initial or prolonged hospitalised medical interventions (Food and Drug Administration. 
2016). Oral anticoagulants are among the most common medication which have contributed to 
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ADEs that required hospitalisation in NSW, Australia (13.5%; n=315,274) (Zhang et al. 2019). 
Haemorrhages, of varying types, are the most commonly reported ADEs while taking oral 
anticoagulation (Anderson & Cifu 2018).  
 
Hospitalisation for anticoagulant related events may also be due to treatment failure, which 
includes the occurrence of primary or recurrent venous thromboembolism (VTE) or ischaemic 
stroke (McIlroy et al. 2018). VTE is the blockage of a blood vessel by a clot and accounts for 
14,000 hospitalisations in Australia each year (Clinical Excellence Commission 2014). This 
condition includes both deep vein thrombosis (DVT), a clot in the deep venous system, most 
commonly in the legs; and pulmonary embolism (PE), a blood clot that breaks away from the 
deep veins and blocks the pulmonary arteries of the lungs (AMH 2018; Clinical Excellence 
Commission 2014). Oral anticoagulants are the most common medications used for the 
treatment and prevention of VTE and are also indicated for non-valvular atrial fibrillation 
(NVAF), the most common cause of ischaemic stroke. An estimated 250,000 Australians are 
currently taking, or have been prescribed, oral anticoagulants (Scott 2017). For almost 60 years, 
warfarin, a vitamin K antagonist (VKA), had been the only oral anticoagulant available in 
Australia (Kakkos et al. 2014). More recently, non-vitamin K antagonist oral anticoagulants 
(NOACs), also referred to as direct oral anticoagulants (DOACs) (McCaughan 2017), became 
accessible, providing clinicians a choice of therapy. There are currently three NOACs available 
in Australia, defined by their mechanism of action; apixaban and rivaroxaban are factor Xa 
antagonists and dabigatran, a direct thrombin inhibitor (AMH 2018; Chin & Doogue 2016).  
 
The Pharmaceutical Benefits Scheme (PBS) provides subsidised prescription drugs to Australian 
residents (Department of Health 2019) and is a good source of population rate analysis for 
medication usage. The PBS was first introduced in the mid to late 1940s with a focus on 
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expensive and life-saving drugs, not becoming fully comprehensive until 1960 (Goddard 2014). 
When warfarin became approved for human use in Australia in 1954 (Kamien 2006), the PBS 
was new and subsidy item codes issued for warfarin were based on the drug strength rather than 
subset codes for each indication for use. The unavailability of PBS subset codes for warfarin 
eliminates the scope to make direct retrospective comparisons of ADEs between oral 
anticoagulants by indication. In 2013, rivaroxaban, and later in 2015, apixaban, gained PBS 
approval for stroke prevention in NVAF and the treatment and prevention of VTE (Chin & 
Doogue 2016; Department of Health 2016; Pratt et al 2016). Although dabigatran gained PBS 
subsidisation for use in stroke prevention in 2013, it did not gain subsidisation for use in the 
prevention of recurrent VTE. Therefore, dabigatran cannot be used to investigate direct 
comparisons for rates of ADEs for all indications with rivaroxaban, apixaban and warfarin, 
which is why dabigatran has been omitted from this research.  
 
During the financial years July 2015 to June 2019, the Australian Therapeutics Goods 
Association (TGA) Database of Adverse Event Notifications (DAEN), which is dependent on 
voluntary reporting, found that oral anticoagulant therapies (apixaban, rivaroxaban and warfarin) 
contributed to 980 of the reported ADEs in Australia, which primarily included VTEs, 
haemorrhage and stroke (Department of Health 2019). However, the DAEN identified 
considerably more ADEs associated with both rivaroxaban (n= 524) and apixaban (n= 342) use, 
between 2015 and 2019, compared to warfarin (n=114) (Department of Health 2019). Existing 
literature has found, when compared to warfarin, apixaban poses lower risk of stroke and major 
bleeding, while rivaroxaban poses similar risks of stroke and major bleeding (Yao et al. 2016). 
Early studies have shown no significant difference in VTE recurrence rates between NOACs and 
warfarin (Castellucci et al. 2014; Streiff et al. 2016).  
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A Pharmaceutical Society of Australia conference presentation by the Master’s candidate, was 
based on the findings of a pilot study which reviewed retrospective admissions to an Australian 
principal referral hospital between January and June 2016 (Watts 2017). The pilot study found 
that 37 of 260 (14.2%) admissions for VTE (ICD-10-AM (9th edition) codes I80.0, I80.2, I82.8, 
I260 and I269) were among individuals taking oral anticoagulants on admission (14 taking 
rivaroxaban, 19 taking warfarin and 4 taking apixaban), suggesting comparison of ADEs 
between oral anticoagulants merited further investigation.  
 
Based on the evidence that at least 50% of all ADEs are preventable (Simper et al. 2017; Woo et 
al. 2020) and the majority of oral anticoagulant ADEs (53% NOAC and 61% warfarin) are also  
preventable (Sennesael et al. 2018), this thesis explores several physiological and preventable 
behavioural factors that are believed to contribute to oral anticoagulant-related ADEs, some of 
which are difficult to ascertain based on limited evidence. For example, the eligibility criteria for 
randomised controlled trials are often very strict and exclude people living with comorbid 
conditions, such as renal impairment and thrombophilia, which may negatively impact upon 
patient outcomes (Burness & Perry 2014; NPS 2013). Existing literature is sparse regarding the 
impact of poor patient knowledge and medication adherence to NOACs, as compared to warfarin 
and their impact of ADEs. Furthermore, there is a paucity of population-based research into the 
ADEs and treatment failure of NOACs when taken for any indication in the post-marketing 
period, which is why there is an urgent need for a comparative investigation of warfarin and 
NOACs, which may provide invaluable future guidance for prescribing physicians.  
 
Based on the limited post-marketing research of ADEs for NOACs versus warfarin and the 
preliminary findings from the pilot study (undertaken by the Master’s candidate), this thesis 
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describes the research which investigated and compared the rates of NOAC and warfarin-related 
ADEs for any indication, which resulted in hospitalisation.  
 
1.2 Thesis aims and hypotheses 
 
The principal aim of this research was to compare the rates of adverse drug events for 
individuals prescribed oral anticoagulants warfarin (vitamin K antagonist) and the non-vitamin 
K antagonists, apixaban and rivaroxaban, for all indications. 
 
There were two secondary aims for this research: 
1. To identify contributing factors to ADEs with the oral anticoagulant warfarin (vitamin K 
antagonist) and the non-vitamin K antagonists, apixaban and rivaroxaban, for all 
indications. 
2. To explore whether patient knowledge or adherence were potential contributing factors 
to recurrent VTE while treated with apixaban or rivaroxaban for DVT or PE.  
 
There were three hypotheses for this research: 
1. Rates of VTE ADEs were higher among patients taking NOACs than patients taking 
warfarin. 
2. Rates of haemorrhage and ischaemic stroke ADEs were no different among patients 
taking NOACs compared to warfarin. 
3. Impaired renal function, comorbidities, age, sex, residential region, poor patient 
knowledge and medication adherence were contributing factors to ADEs among patients 
taking oral anticoagulants. 
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Oral anticoagulants are the primary medication therapy used to treat and help prevent VTE, 
essentially DVT and PE (Bauer 2013), with an incidence rate in Australia of 1.5 per 1,000 
people per year (Stevens et al. 2019). Oral anticoagulants are also indicated in stroke prevention 
for ‘at risk’ patients living with NVAF (Basaran et al. 2015), however atrial fibrillation (AF) is 
the not the main focus of this research and has been included to facilitate a robust comparison 
between warfarin and NOACs using PBS prescription data.  
 
This literature review will compare and contrast warfarin and NOACs (apixaban and 
rivaroxaban) in terms of their pharmacokinetic profiles, potential for ADEs, and factors that can 
affect their therapeutic responses.  
 
2.2 Search strategies 
 
The MEDLINE database on the OVID® platform was searched between 2010 and 2020, using 
the search terms: venous thromboembolism, VTE, pulmonary embolism, PE, recurrence, 
haemorrhage, ischaemic stroke, Eliquis®, apixaban, rivaroxaban, Xarelto®, warfarin, 
Coumadin®, Marevan® and adverse drug event. The search strategy can be found in Appendix 
1.  
 
The search yielded 6,278 articles. Application of the inclusion criteria depicted in Figure 2, 
which included articles published post 2010, written in English and review articles with human 
participants resulted in the exclusion of 6,150 articles. In addition to the 128 articles identified 
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from the search strategy and inclusion criteria, articles pertaining to prescribing habits, which are 
not indexed in international literature, were also included in the literature review. These articles 
were sourced by searching Google Scholar® and the grey literature and resulted in an additional 
17 articles/references. In total, 145 articles/references were screened for relevance and a further 
83 were excluded because they were based on other ADEs not relevant to anticoagulants, 
alternate therapies or specific population groups, for example cancer, that are not the focus of 
this thesis.  
  
Figure 2- PRISMA Flow Diagram 
 
Thesis | Kerry Watts 
 
Page | 22  
 
2.3 Literature review findings  
 
In total, 62 articles contributed to this review. These included seven medication information data 
bases, for example the Australian Medicines Handbook, and Australian government guidelines. 
The articles included four systematic reviews and meta-analyses, eight quantitative studies, 
seven randomised clinical trials, thirty-two literature reviews and four case reports. The majority 
of the articles (n=51) were conducted in the United States (US), Canada, the United Kingdom 
(UK) and Europe, with only four studies conducted in Australia. 
 
The following provides a summary of key findings from the literature review under five 
subheadings: ADEs; Mechanism of action and pharmacokinetics of oral anticoagulants; Current 
prescribing patterns of oral anticoagulants in Australia; Potential ADEs associated with oral 
anticoagulants; and Contributing factors to ADEs. 
 
2.3.1 Adverse drug events 
 
Adverse Drug Events (ADEs) include injuries resulting from the use of a drug, and includes 
harm caused by Adverse Drug Reactions (ADRs), harm from the use of the drug (including dose 
reductions and discontinuations), as well as harm from medication errors (Piazza et al. 2011). 
ADRs range from common side-effects, including gastrointestinal upset; to allergic reactions, 
including rash; or even life threatening anaphylaxis (Smith 2013). Most ADRs are dose-related 
and predictable (Marsh 2018). Conversely, medication errors are defined by unpredictable 
inaccuracies in prescription, transcription, dispensing or administration of medications 
(Runciman et al. 2003). A US study, which investigated 463 anticoagulant-associated 
Thesis | Kerry Watts 
 
Page | 23  
 
hospitalisations for ADEs, found that 226 hospitalisations were the result of medication errors 
(48.8%) and 141 were ADRs (30.5%) (Piazza et al. 2011).  
 
In total, ADEs in the US, account for an estimated 1 million ED visits and 125,000 hospital 
admissions per year (U.S. Department of Health and Health Services 2020), while in Australia it 
is estimated that 2 to 3% of all hospital admissions per year are medication related (Australian 
Commission on Safety and Quality in Healthcare 2017). Due to these estimates, developing 
strategies to reduce ADEs have been made a national health priority (Australian Commission on 
Safety and Quality in Healthcare 2017), primarily because a large proportion of these ADEs are 
deemed to be preventable (Snyder & Fields 2010). According to the literature, between 28 and 
80% of all ADEs are preventable (Woo et al. 2020) and up to 70% of all anticoagulant-
associated ADEs are preventable (Piazza et al. 2011; Runciman et al. 2003). Given that this high 
proportion of anticoagulant related ADEs are potentially preventable, there is clearly a need for 
further research to compare the number of severe ADEs associated with the different 
anticoagulants and factors which may contribute to the ADEs.  
 
2.3.2 Mechanism of action and pharmacokinetics of oral anticoagulants 
 
Currently available oral anticoagulants prescribed for the treatment and/or prevention of VTE 
include warfarin, apixaban and rivaroxaban. Warfarin is a vitamin K antagonist (Table 1), that 
inhibits the vitamin K-dependent synthesis of clotting factors II,VII, IX and X in the liver 
(Vandiver et al. 2014), and decreases the natural anticoagulant regulatory proteins C and S 
(Minuk et al. 2010); thus reducing the coagulant ability of the blood and helping to treat and 
prevent VTE. Apixaban and rivaroxaban selectively inhibit clotting factor Xa (Table 1), 
blocking thrombin production and the conversion of fibrinogen to fibrin (Bauer 2013). 
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Warfarin is completely absorbed after oral administration (Tadros & Shakib 2010) and hepatic 
enzymes, cytochrome P450 (CYP) (Table 1) are responsible for the metabolism and elimination 
of warfarin (Tadros & Shakib 2010). Although warfarin demonstrates a peak concentration time 
of four hours (Table 1), the peak therapeutic effect may not be achieved until 72 to 96 hours 
after administration (Medscape 2016). The long half-life of warfarin (20-60 hours) is directly 
related to the long half-lives of the vitamin K-dependant clotting factors, as well as the C and S 
proteins (Kaztung et al. 2017). Due to the delayed onset of therapeutic action of warfarin, when 
used for the treatment of VTE, a bridging period with an injectable anticoagulant is required 
until a therapeutic level is established (Hillis & Crowther 2014).  
 
Individualised dosing is required with warfarin therapy because of its narrow therapeutic index 
and unpredictable pharmacokinetics (Hillis & Crowther 2014; Viprey et al. 2017). The 
therapeutic level of warfarin is expressed numerically as a surrogate measure of the time taken 
for the blood to clot, commonly known as the international normalised ratio (INR) (Nelson et al. 
2015). The aim of therapy is to keep the INR between 2 and 3 and the ‘time the INR spends in 
therapeutic range’ (TTR) should be above 70% to avoid treatment failure (Jordan 2015). This is 
important because an INR below 2 is subtherapeutic and increases the risk of thromboembolism, 
whereas an INR above 3 is supratherapeutic and increases the risk of haemorrhage events, 
especially among older people (Ahmad & Lip 2012).  
 
In contrast to warfarin, apixaban and rivaroxaban display predictable pharmacokinetics, with a 
rapid onset of action, resulting in a therapeutic response within one hour (McBane & Marshall 
2017) and a peak concentration within three hours (Table 1). This rapid onset of action means 
that unlike warfarin, there is no requirement for bridging with an injectable anticoagulant for the 
treatment of VTE (Hillis & Crowther 2014; Viprey et al. 2017). Furthermore, NOACs 
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demonstrate a much shorter half-life (5-14 hours) than warfarin (Table 1) signifying that regular 
dosing is imperative for maintaining therapeutic levels as the anticoagulant effect dissipates 
quickly. 
 
Although both NOACs and warfarin undergo metabolism by hepatic CYP enzymes, warfarin is 
almost completely metabolised in the liver (99%), as compared to the NOACs which are mainly 
eliminated via the renal system (Table 1). In contrast to warfarin, 25% of apixaban and 33% of 
rivaroxaban are excreted by the renal system (Hinojar et al. 2015) and the remainder converted 
in the liver or eliminated in the faeces (Bauer 2013). Therefore, kidney function and potentially 
liver function are important considerations when NOACs are prescribed. 
 
Table 1- Mechanism of action and pharmacokinetics of anticoagulants (AMH 2018; MIMS 
Australia 2016; Vandiver et al. 2014) 
 
Key: CrCl= Creatinine Clearance. This is a surrogate measure of kidney function by estimating the rate that 
creatinine is cleared. 
 
2.3.3 Current prescribing patterns of oral anticoagulants in Australia 
 
In 2015, there were approximately 250,000 Australians receiving prescriptions for oral 
anticoagulants (Scott 2017). Prior to and since that time, the number of Australians being 
prescribed NOACs has been steadily increasing. For example, prescriptions for rivaroxaban for 
Anticoagulant Warfarin Apixaban Rivaroxaban 
Mechanism of action Vitamin K 
antagonist 
Direct factor Xa 
inhibitor 
Direct factor Xa 
inhibitor 
Half life 20-60 hours 9-14 hours 5-13 hours 
Time to peak 4 hours 3 hours 3 hours 
Renal excretion Nil  25% 33% 
Renal Contraindications Nil CrCl <25mL/min CrCl <30mL/min 
CYP enzyme metabolism 99% 15% 32% 
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VTE prophylaxis after orthopaedic surgery, have increased from 100,000 in 2013 to almost 1.5 
million in 2016, while prescriptions for warfarin have declined from 2.45 million in 2012 to 1.85 
million in 2016 (Department of Health 2016). In 2015, patients starting oral anticoagulant 
therapy for NVAF, for the first time, were more likely to commence on a NOAC rather than 
warfarin (Department of Health 2016). The NOAC prescription numbers continued to increase 
as apixaban or rivaroxaban became the preferred anticoagulation among Australian prescribers 
for treatment and prophylaxis of VTE (Stevens et al. 2019), particularly for individuals with 
unstable INR likely to miss follow up appointments (Generalova et al. 2018). Clinician 
knowledge of the dosing complexities of NOACs for the treatment and prevention of VTE could 
be a major contributing factor to the risk of ADEs. For example, NOACs have been promoted as 
having simplistic dosing regimens which do not require regular monitoring (Vutukuri et al. 
2015). In comparison to the daily dosing schedule for warfarin, Table 2 outlines the multiple 
dosing schedules required for NOACs depending on the different indications. It is recommended 
that high risk individuals with complicated comorbidities, or previous recurrent VTE while 
taking rivaroxaban 10 mg daily, are to be prescribed a higher dose of rivaroxaban (20 mg daily) 
(Electronic Medicines Compendium 2018). The complicated dosing regimen for NOACs is a 
potential contributing factor for ADEs, especially when the Australian guidelines for NVAF 
were updated in 2018 to recommend NOACs as first choice over warfarin (Brieger et al. 2018) 
and clinicians treating acute VTE were advised to prescribe factor Xa inhibitors as the first 
choice anticoagulant (Tran et al. 2019).  
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Table 2- Complex fixed-dose regimens for treatment and prevention of VTE  
NOAC Apixaban Rivaroxaban 
Prevention of VTE in hip/knee 
replacement 
2.5 mg twice daily 
Duration: hip 32-38 days; knee 
10-14 days 
10 mg once daily 
Duration: hip 5 weeks; knee 2 
weeks 
Treatment of VTE 10 mg twice daily for 7 days 
then 5mg twice daily 
15 mg twice daily for 3 weeks 
then 20 mg once daily 
Prevention of recurrent VTE 2.5 mg twice daily after at least 
6 months of treatment of DVT 
or PE 
10mg or 20 mg once daily for 
up to 12 months 
* Retrieved from MIMS Australia (2016). 
 
2.3.4 Potential adverse events associated with oral anticoagulants  
 
All oral anticoagulants have the potential to cause ADEs resulting in unplanned hospitalisations, 
which include haemorrhage (bleeding) (Khan & Datta 2015) or treatment failure, including VTE 
events (Lutsey et al. 2019) and ischaemic stroke while taking an oral anticoagulant (Brieger et 
al. 2018).  
 
2.3.4.1 Haemorrhage  
 
Bleeding is the most common ADE reported with oral anticoagulant use and can be life 
threatening, so the benefits and risks of anticoagulation require careful consideration before 
commencing therapy (Khan & Datta 2015). The evidence regarding the incidence of all bleeding 
events associated with taking either warfarin or NOACs is variable and inconsistent. A review of 
Phase III clinical trials report higher bleeding events within 6 to 12 months of warfarin therapy 
(10%), in comparison to NOACs (4%–9%) (Toth 2016). However, a longitudinal Danish study 
which included 61,678 patients prescribed oral anticoagulation for AF, between 2011 and 2015, 
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found comparable total annual bleeding events for warfarin (5.0%; n=35,436) and rivaroxaban 
(5.3%; n= 7,192) but lower for apixaban (3.3%; n= 6,349) (Larsen et al. 2016). The evidence is 
conflicting regarding the bleeding-related ADEs associated with both NOACs and warfarin, 
therefore requiring further investigation in a real-world post phase III clinical trial setting. 
Another area worth investigating in a real-world setting, is the difference in the severity of 
adverse bleeding events for both warfarin and NOACs which can range in severity from non-
major to major bleeding events (Khan & Datta 2015).  
 
Clinically relevant non-major bleeding events 
 
Clinically relevant non-major bleeds (CRNMB) are haemorrhagic events which require 
healthcare intervention and include, but are not limited to, epistaxis (nose bleeds) and mild rectal 
bleeds (Khan & Datta 2015). Studies have cited the benefits of NOACs in comparison to 
warfarin, especially with regard to the reduction in CRNMB (Adam et al. 2013; Rollins et al. 
2014; Van Es et al. 2014). These findings concur with an Australian study, that reported on 379 
hospital admissions with a primary diagnosis of minor bleeding (Roberts et al. 2016). In this 
study, hospital admissions were more prevalent for patients taking warfarin, as compared to 
patients taking NOACs (17.8/1,000 years versus 5.2/1,000 years, respectively) (Roberts et al. 
2016). However, in contrast to these findings, a review of 8,000 participants with a mean age of 
between 55 and 58 years, included in the EINSTEIN DTV and EINSTEIN PE trials, reported no 
significant difference in CRNMB events between rivaroxaban (28.3%) and warfarin (28.0%) 
(Burness & Perry 2014). The exception to these results were the elderly patient population, aged 
75 years and above, who experienced higher rates of CRNMB bleeding with rivaroxaban when 
compared to warfarin (Burness & Perry 2014). This conflicting evidence suggests that more 
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research is required to ascertain whether NOACs or warfarin are more or less likely to contribute 
to CRNMB. 
 
Major and gastrointestinal bleeding events 
 
The definition for major bleeding encompasses more than a 2 gram/Litre drop in haemoglobin, 
bleeding into a critical site, including intracranial bleeding, and the requirement for blood 
transfusions (Beyer-Westendorf et al. 2014). Gastrointestinal (GI) haemorrhage is often 
classified as a major bleed and is well documented while taking oral anticoagulants. In their 
analysis of 13,130 patients, Abraham et al (2017) found that apixaban was the preferred NOAC 
in patients at risk of GI bleeding, demonstrating a significant reduction (P<0.001) in the 
incidence of GI haemorrhage when compared to rivaroxaban (1.34/100 patient years versus 
3.54/100 patient years). These findings are supported by a US study, which investigated 32,350 
patients, and reported significantly higher (P=0.03) GI bleeding in patients taking rivaroxaban 
(3.26/100 person years), as compared to those taking warfarin (2.53/100 person years) (Amin et 
al. 2017). Notably, another study, which included 18,201 patients, found that there was no 
significant difference in GI haemorrhagic events between apixaban (0.76% events per year) and 
warfarin (0.86% events per year) (Granger et al. 2011). 
 
In contrast to this evidence, a systematic review and meta-analysis which included nearly 38,000 
participants from Phase III clinical trials, found that lower rates of major bleeding events have 
been associated with NOACs (1.08%) compared to warfarin (1.73%) (Kakkos et al. 2014). In 
support of these findings, another Phase III trial provided evidence for the reduction of 
intracranial haemorrhage events with NOACs when compared to warfarin (Van Es et al. 2014). 
Similarly, Granger et al (2011) found that less than half the reported major bleeding events were 
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experienced among patients treated with apixaban (0.33% per year), as compared to those 
treated with warfarin (0.80% per year).  
 
Overall, lower rates of major haemorrhagic events were documented for rivaroxaban when 
compared to warfarin, however these are not as common as the marked increase in 
gastrointestinal bleeding events (Amin et al. 2017). Apixaban, a relatively new NOAC, appears 
to be associated with fewer bleeding related ADEs compared to the other oral anticoagulants, 
including both rivaroxaban and warfarin. These findings, are based on clinical trials which are 
often funded by drug companies and exclude participants with co-morbid risk factors, such as 
hypertension, renal impairment and high risk of bleeding, which may have an impact on the 
results (Kakkos et al. 2014). In addition, individuals may only require NOAC treatment for six 
months (AMH 2018), however considerable haemorrhagic events have been found within 30 
days of rivaroxaban initiation (Chen et al. 2016). This highlights the importance of considering 
bleeding risk on initiation of treatment and the need for further comparative studies to 
investigate whether NOACs are less likely than warfarin to cause bleeding related ADEs in a 
real-world setting, particularly given the lack of Therapeutic Goods Authority (TGA) approved 
reversal agents available in Australia for apixaban and rivaroxaban. Several observational 
studies which have been published since commencement of this research and contribute to the 
overall body of knowledge regarding bleeding related ADEs associated with the different 
anticoagulants are incorporated in the discussion.  
 
2.3.4.2 Venous thromboembolic events  
 
For the purpose of this thesis, the development of VTE while taking oral anticoagulants 
prophylactically or the development of a recurrent VTE while being treated for VTE, will be 
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defined as treatment failure. This section of the literature review highlights inconsistent evidence 
regarding comparative incidence of recurrent VTE, which by definition for this thesis is referring 
to treatment failure.  
 
An annual VTE recurrence rate of between 3-12% has been reported in a systematic review and 
meta-analysis which included over 14,000 patients (Rollins et al. 2014). Given that recurrent 
VTEs are complications experienced by up to 50% of uncoagulated patients within 10 years after 
their first VTE episode (Thachil 2012), this can have important health care cost implications in 
Australia, where VTE accounts for 14,000 hospitalisations each year (Clinical Excellence 
Commission 2014). It is important therefore, to gain a better understanding about whether or not 
anticoagulants, and if possible which types of oral anticoagulants, are a contributing factor to 
recurrent VTEs (i.e., treatment failure). 
 
According to data available from the DAEN, a voluntary reporting system established in 1971 
(TGA 2017) which includes notifications of mild to severe ADEs that may or may not have 
resulted in hospitalisation, anticoagulant-related VTE events occur more commonly with 
NOACs compared to warfarin (Department of Health 2019). Records accessed from this 
database, between 1 January 1971 to 1 September 2019, suggest that rivaroxaban was 
responsible for the largest proportion of PE (4.2%) and DVT (3.7%) reports, followed by 
apixaban (PE 2.4%; DVT 2.4%) and then warfarin (PE 0.3%; DVT 0.4%) (Table 3).  
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Table 3- Number of reports for DVT and PE while taking anticoagulation 1971-2019 
 
Anticoagulant Total number of 
reports 
PE 
Number of reports 
(%) 
DVT 
Number of reports 
(%) 
Apixaban  978 31 (3.2) 28 (2.9) 
Rivaroxaban  2123 98 (4.6) 81 (3.8) 
Warfarin  2360 8 (0.3) 10 (0.4) 
*Data retrieved from DAEN report (Department of Health 2019) 
 
Data available from DAEN, accessed on 1 December 2019, documented unresolved VTE or 
VTE recurrence as the second highest reported ADE associated with rivaroxaban use (8.6%), 
and the fourth most reported ADE for apixaban (5.7%), in comparison to 1.1% for warfarin 
(Department of Health 2019) (Table 4).  
 
Table 4- Number of reports for drug ineffective while taking anticoagulation 1971-2019  
Anticoagulant Total number of 
reports 
Drug ineffective 
Number of reports (%) 
Apixaban  978  56 (5.7) 
Rivaroxaban  2123  183 (8.6) 
Warfarin  2360  27 (1.1) 
*Data retrieved from DAEN report (Department of Health 2019) 
 
 
Although this data provides a foundation of curiosity to warrant further investigation, there are 
limitations of this database because the notifications are voluntary. In addition, it needs to be 
acknowledged that warfarin had already been used clinically for 17 years, prior to the 2017 
establishment of the DAEN database, and that the NOACs have only be available in Australia 
since 2013. In other words, the data reported in DAEN, between 1971 and 2019, are potentially 
missing 17 years of warfarin related ADEs, only reports on 6 years or less of NOAC related 
ADEs, and provides no record of how long the patient was receiving treatment prior to 
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experiencing the ADE. Furthermore, there may be a greater interest among clinicians in 
reporting ADEs for newer drugs (e.g., NOACs) compared to older drugs (e.g., warfarin), 
demonstrated by the paucity of reports regarding warfarin. This also supports the need for 
comparative population research.  
 
Focusing on a broader international context, a systematic review and meta-analysis involving 45 
randomised controlled trials conducted worldwide with 44,989 patients concluded that there 
were no noteworthy differences in rates of recurrent VTEs among patients treated with NOACs 
verses those treated with warfarin (Castellucci et al. 2014). These findings were supported by 
Van Es et al. (2014) who undertook a meta-analysis of six Phase III clinical trials, including 
27,023 patients, which identified non-inferior recurrent VTE outcomes for NOACs (2.0%) and 
warfarin (2.2%) (Van Es et al. 2014). Similarly, the AMPLIFY trial, which consisted of 2,609 
patients taking apixaban and 2,635 patients taking warfarin, concluded apixaban was non-
inferior to warfarin in the prevention of recurrent VTEs (RR 0.84, 95% CI -0.60-1.18) (Agnelli 
et al. 2013). No difference in recurrent VTEs were also found in the XALIA trial (n=5,142) 
which compared the hazard rates or mortality rates for rivaroxaban and warfarin (HR 0.77, 95% 
CI 0.40-1.50, P=0.44) (Franchini & Mannucci 2016), and similarly in the EINSTEIN trials 
(EINSTEIN DVT investigators 2010; EINSTEIN PE investigators 2012).  
 
A meta-analysis provided evidence of potential limitations to non-inferiority clinical trials when 
NOACs are prescribed outside of the strict participant selection criteria, suggesting non-
representation of the general population (Burness & Perry 2014). The diversity from these 
findings and the suggestion that population-based research may display different results, 
identifies the need for further research into ADEs of NOACs compared to warfarin in VTE 
treatment and prevention. 
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2.3.4.3 Ischaemic stroke 
 
Ischemic stroke accounts for up to 85% of stroke incidence (Milling & Frontera 2017) and based 
on randomised clinical trials, NOAC use is associated with similar or reduced risks of stroke 
when compared to warfarin and are recommended as first line for stroke prevention in patients 
with AF (Gurol 2018). Large-scale Phase III trials for apixaban and rivaroxaban concluded non-
inferiority for prevention of stroke when compared with warfarin (Brieger et al. 2018). A meta-
analysis involving 94,656 participants found a reduction in odds ratio for stroke or systemic 
embolism for apixaban of 0.79 (95% CI, 0.66-0.94) and for rivaroxaban of 0.88 (95% CI, 0.74-
1.03) when compared with warfarin (López-López et al. 2017). The ARISTOTLE clinical trial 
(n=18,201 participants) found apixaban to be superior in reducing the incidence of stroke 
(1.27%) compared to warfarin (1.60%) (Granger et al. 2011). In addition, a longitudinal US 
population-based cohort study, including 148,446 participants, found the incidence of ischaemic 
stroke, while taking warfarin for AF, to be 4.0% (n=6,006) (Tung et al. 2015), while the 
XANTUS trial, one of the first prospective real-world studies for rivaroxaban in AF patients, 
concluded that 1.6% (n=6,784) of patients experienced a symptomatic ischaemic stroke 
(Kocabas et al. 2016). The evidence of clinical trials and real-world studies supports the benefits 
of NOACs compared with warfarin in stroke reduction in AF, although there is a lack of 
research into the risk of stroke as an ADE when prescribed oral anticoagulation for any 
indication, including VTE treatment and prophylaxis, highlighting the need for additional 
research in a real-world setting. 
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2.3.5 Contributing factors to ADEs with oral anticoagulants 
 
Several factors can contribute to ADEs with oral anticoagulants including physiological factors, 
such as renal impairment (Hillis & Crowther 2014), hepatic impairment (Northup & Caldwell 
2013), interactions which include both drug and food interactions (Vandiver et al. 2014), 
therapeutic INR control (Nelson et al. 2015) and malignancy (American Society of Clinical 
Oncology 2019). Other factors include thrombophilia (Skelley et al. 2017) and individual 
patient-related behaviours, such as medication adherence (Scholefield & Wilcken 2017).  
 
For the purpose of this thesis, factors which may contribute to anticoagulant related ADEs that 
were investigated included; renal impairment, thrombophilia, medication adherence and 
therapeutic INR control. Review of medication errors due to drug interactions were reliant on 
accurate and complete medication histories which were not always available and therefore 
considered outside the scope of the current research. Hepatic impairment required calculation of 
Child-Pugh scores together with a number of biochemistry results which were not available for 
all patients and were also considered outside the scope of this study. In addition, individuals with 
malignancy were excluded from this study because at the time of designing this study, the 
efficacy of NOACs in patients with malignancy was not clearly defined (Sardar et al. 2015) and 
because this patient cohort were typically excluded from clinical trials (Agnelli  et al. 2013).  
 
2.3.5.1 Renal impairment 
 
The use of oral anticoagulants in patients with renal impairment can be associated with an 
increased risk of ADEs and in particular bleeding, making the dosing and selection of 
anticoagulants important for this patient group (Hillis & Crowther 2014). The degree of renal 
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impairment is often classified according to patients’ creatinine clearance (CrCl), which is a 
surrogate measure of renal function (Chin & Doogue 2016). Based on creatinine clearance 
values, renal impairment can be categorised as mild (CrCl 25-49mL/min), moderate (CrCl 10-
24mL/min) or severe (CrCl <10mL/min) (AMH 2018). In current practice, warfarin is not 
contraindicated in moderate to severe impairment as doses are titrated to individual patient 
responses according to their international normalised ratio (INR), thus warfarin therapy does not 
require dose adjustments based specifically on renal impairment (Amin et al. 2017). A US study 
which assessed the long-term safety of warfarin in 187 patients (aged less than 50 years to over 
70 years) with co-morbidities, including renal impairment, concluded that there were no 
significant increase in bleeding for the 23 patients with renal impairment who were on warfarin 
(Khan & Datta 2015). Warfarin therefore, remains a well-tolerated anticoagulant for long-term 
treatment and prevention of VTE for patients with renal impairment. 
 
Apixaban is contraindicated for use in patients with a CrCl< 25mL/min and rivaroxaban in 
patients with a CrCl <30mL/min (AMH 2018; Vandiver et al. 2014) and require calculations of 
renal function using the Cockcroft-Gault formula before prescribing this class of oral 
anticoagulants (Mekaj et al. 2015). A meta-analysis of eight randomised controlled trials (10,616 
participants), was conducted to compare NOACs with warfarin among patients diagnosed with 
AF and VTE (Harel et al. 2014). The meta-analysis found NOACs to be non-inferior to warfarin 
in the risk of haemorrhage (RR 0.89, 95% CI, 0.68-1.16) or recurrent VTE (RR 0.97, 95% CI, 
0.43-2.15) when comparing the safety and efficacy of oral anticoagulation in patients with mild 
renal impairment (CrCl 30-50mL/min) (Harel et al. 2014). A recent review of chronic kidney 
disease and NOAC use concluded that individuals taking oral anticoagulation with renal 
impairment had a higher risk of ischaemic stroke and haemorrhage, compared to individuals 
with normal renal function (Heine et al. 2018). Although studies have reported the safe and 
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efficacious use of NOACs in mild renal impairment, there is limited evidence to support the safe 
use of NOACs in moderate to severe renal failure, especially in a post marketing real-world 
setting.  
 
The pharmacokinetics of NOACs suggest that renal impairment decreases the excretion of these 
drugs, resulting in increased plasma concentrations (Hillis & Crowther 2014). A review of the 
rivaroxaban EINSTEIN trials (8,000 participants), noted that the blood concentration of 
rivaroxaban was increased by 1.2 to 1.6-fold in patients with varying levels of renal impairment 
(Burness & Perry 2014). These increases in blood concentration would consequently increase 
the risk of haemorrhage (Chin & Doogue 2016; Hillis & Crowther 2014). In addition, a recent 
real-world observational study for rivaroxaban use in AF noted renal impairment (CrCl<50 
mL/min) for 9.4% (638/6784) of participants (Kocabas et al. 2016) and resulted in an increased 
proportion of major haemorrhage (1.9%), than previously reported in clinical trials (1.08%) 
(Kakkos et al. 2014). Patients with severe renal impairment often have complex comorbidities, 
which is why warfarin remains the oral anticoagulant of choice in this patient cohort (Harel et al. 
2014; Lutz et al. 2017).  
 
Although NOACs are marketed with the benefits of not requiring the regular monitoring 
involved with warfarin, variable dose recommendations based on creatinine clearance are 
necessary for the safe use of NOACs. It is important for renal function to be monitored on 
initiation of therapy with NOACs, and throughout treatment, to provide dose adjustments as 
required. Based on this evidence it was decided to investigate renal function as a potential 
contributor to anticoagulant related ADEs in the current study.  
 
 
Thesis | Kerry Watts 
 
Page | 38  
 
2.3.5.2 Thrombophilia 
   
Thrombophilia is an abnormality of blood coagulation that increases the risk of VTE (Hillis & 
Crowther 2014), commonly classified as factor V Leiden, prothrombin gene mutations (Hillis & 
Crowther 2014) or antiphospholipid syndrome (APS) (Signorelli et al. 2016). Although 
historically treated with warfarin (Skelley et al. 2017), recent evidence suggests that common 
thrombophilia are considered to have little influence on recurrent VTE (Stevens et al. 2019). 
Based on their pharmacologic activity, NOACs are considered as a potential alternative to 
warfarin (Skelley et al. 2017). A meta-analysis of Phase II and Phase III randomised clinical 
trials found no significant difference in risk of bleeding or recurrent VTE related ADEs between 
individuals with thrombophilia taking NOACs (excluding apixaban) compared to warfarin 
(haemorrhage RR 0.92, 95% CI 0.62-1.36; recurrent VTE RR 0.70, 95% CI 0.34-1.44) (Elsebaie 
et al. 2019). In contrast to this evidence, a randomised controlled trial in Spain, including 190 
patients with antiphospholipid syndrome, concluded significantly more ADEs with rivaroxaban 
compared to warfarin, including recurrent VTE (RR 1.83, 95% CI 0.71-4.76) and stroke (RR 
19.00, 95% CI 1.12-321.9) (Ordi-Ros et al. 2019). The evidence remains limited and 
inconclusive for the use of NOACs in thrombophilia and therefore post-marketing surveillance is 
imperative.  
 
2.3.5.3 Medication adherence and INR control 
 
Poor adherence by patients to warfarin as oral anticoagulant therapy is well known to contribute 
to poor therapeutic outcomes (Scholefield & Wilcken 2017), with early studies anticipating the 
same for rivaroxaban and apixaban (Chin & Doogue 2016; Granger et al. 2011; Harel et al. 
2014). Based on the findings of an Australian study, between 30-60% of patients are non-
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adherent to prescribed medications (Leung et al. 2017). It is important therefore, to consider that 
poor medication adherence can affect therapeutic responses to anticoagulant therapy, including 
NOACS with their much shorter half-lives as compared to warfarin. 
 
Studies conducted in the UK and US suggest that adherence to warfarin therapy varies from 40-
60% (Kearon et al. 2016; Thachil 2012). Warfarin therapy requires regular monitoring until a 
therapeutic INR is achieved. Monitoring is an invasive and complicated process, which is further 
complicated in the treatment of VTE as the patient requires short-term co-administration of 
injectable anticoagulant on initiation of therapy (Hillis & Crowther 2014). During this time, dose 
adjustments to warfarin are made and regular haematological monitoring is required until 
therapeutic levels are achieved. Certainly, the requirement for regular blood tests and 
appointments associated with warfarin therapy can be a risk to adherence and a deterrent for 
many patients (Vandiver et al. 2014). However, it can also be perceived as an advantage of 
warfarin therapy because the INR not only assures therapeutic levels are reached, but it can also 
be an opportunity to monitor for adherence (Nelson et al. 2015). 
 
Time spent in therapeutic range for warfarin therapy is important to avoid treatment failure. A 
US study reviewed INR levels for 9,433 patients taking warfarin to investigate the amount of 
time spent in the therapeutic range, between 2 and 3. In this study, approximately two-thirds 
(67%) of warfarin levels for participants were in the therapeutic range, with 23% being 
subtherapeutic and approximately 16% experiencing supratherapeutic INR values (>3.0) (Nelson 
et al. 2015). In this same study, at subtherapeutic levels, warfarin was less effective for the 
treatment and prevention of VTE and at supratherapeutic levels patients were at risk of 
experiencing haemorrhagic ADEs. It is possible that poor adherence to warfarin therapy 
contributed to time spent outside of therapeutic range, as suggested by the results of a 
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retrospective US study of 1,753 patients, mean age 58 years, which found that poor adherence to 
warfarin resulted in increased VTE recurrence among 7.6% (n=137) of patients, with 
subtherapeutic INR (<2.0) (RR 3.37, 95% CI, 2.16–5.27 per 100 person-years) (Nordstrom et al. 
2015).  
 
The EINSTEIN trials documented improved patient satisfaction with rivaroxaban compared with 
warfarin and suggested better medication adherence with NOACs would reduce the incidence of 
recurrent VTE (Toth 2016). This notion of improved medication adherence for rivaroxaban was 
not supported by a Canadian study of 26,000 patients, which found that 32% of patients 
prescribed rivaroxaban stopped taking the medication for at least two weeks within the first six 
months of treatment (Scholefield & Wilcken 2017) and a meta-analysis comprising 1.6 million 
patients taking NOACs for AF concluded 75.6% adherence (Shehab et al. 2019). These poor 
adherence rates are a concern because, unlike warfarin, there is no recommended routine 
haematological monitoring to determine therapeutic levels. Despite this, NOACs are considered 
a desirable treatment option for many patients (Chin & Doogue 2016). A lack of adherence 
however, can be especially problematic because NOACs have a fast onset and offset of action 
(eMIMS 2016), so if a single dose is missed, this could result in sub-therapeutic drug levels and 
predispose patients to a higher risk of ADEs, including thromboembolic events (Chin & Doogue 
2016; Vandiver et al. 2014). In addition, an Australian patient survey acknowledged that 45.1% 
(n=386) of individuals prescribed NOACs for AF did not have a high level of adherence 
(Obamiro et al. 2018). The findings from this study concluded that the younger cohort, up to 65 
years old, were less likely to have high adherence compared to individuals over 65 years (OR 
0.54, 95% CI 0.33-0.88, P = 0.013) and females demonstrated higher adherence compared to 
males (OR 1.69, 95% CI 1.08-2.64, P = 0.023).  
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Regular monitoring and health professional contact have demonstrated a positive effect on 
medication adherence to warfarin (Nelson et al. 2015). Considering NOACs are recommended 
first line in VTE (Tran et al. 2019) with a fast offset of action and lack of regular monitoring, 
adherence is imperative for efficacy of treatment and reasons for lack of adherence need to be 
further investigated. There are currently no reported studies that focus on adherence in patients 
receiving oral anticoagulants for VTE treatment and prevention, highlighting the need for further 
research into factors affecting patient adherence to oral anticoagulants. If patient adherence is 




Based on the articles included in this review there are a number of gaps that exist in current 
literature. These relate to the many factors which may contribute to oral anticoagulant-related 
ADEs and factors that can impact on therapeutic response. It is therefore important that future 
research, such as the research included in the current thesis which investigates these factors, and 
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3. METHODOLOGICAL APPROACH 
 
This chapter will provide an overview of the methodological approach used in this thesis. The 
research philosophy of pragmatism (Saunders et al. 2012) was used to evaluate the hypotheses 
through application of quantitative and a pilot study of patients with recurrent VTE. The blend of 
statistical testing of the hypotheses, while incorporating human interest, is imperative when 
researching the topic of medication management (Gray 2014). This approach to research is 
common among health researchers (Tariq & Woodman 2013) who use it to provide meaningful 
findings which are relevant and translatable to clinical practice.  
 
The research incorporated two separate studies.  
Study 1 was a retrospective observational cohort study to assess rates of ADEs among people 
prescribed oral anticoagulants (both warfarin and NOACs) for any indication and to identify 
potential contributing factors including renal function. Study 2 was a prospective study including 
patient interviews which assessed the effect of medication knowledge and adherence on 
recurrent VTE among people taking NOACs. The interview included four open-ended questions 
in combination with a validated medication knowledge tool (Obamiro et al. 2016) and 
medication adherence questionnaire (Morisky et al. 1986). Table 5 provides a brief overview of 
the two separate studies.  
Table 5- Research summary 
 






To quantify the rate of hospitalisation 
relating to ADEs while taking an oral 
anticoagulant for any indication and 





2. Patient interview, 
knowledge tool and 
adherence 
questionnaire 
To explore patient knowledge and 
adherence as contributing factors to 
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The population of interest in both studies were residents from the Illawarra Shoalhaven area, the 
third-largest regional economy in New South Wales, Australia (NSW Government 2018). The 
Australian Bureau of Statistics use a geographic framework, the Australian Statistical Geography 
Standard, to publish geographically-standardised statistics. The current standard includes a 
Statistical Area (SA) hierarchy, at levels SA1 through SA4, of which level SA3 is designed for 
output of regional data (Australian Bureau of Statistics 2018). Australia is divided into 358 
standardised regional areas (defined as SA3 regions), each with a population of between 30,000 
and 130,000 people (Australian Bureau of Statistics 2016). The studies include residents from 
four SA3’s in the Illawarra region (10701: Dapto - Port Kembla, 10702: Illawarra Catchment 
Reserve, 10703: Kiama – Shellharbour, and 10704: Wollongong) and one SA3 in the 
Shoalhaven region (11401: Shoalhaven) depicted in Figure 3. The Australian Bureau of 
Statistics National Census of Population and Housing figures for residents, aged 18 years and 
over, at 9 August 2016 was estimated to be 228,808 (Australian Bureau of Statistics 2015-
2017a) for the Illawarra region and 79,848 for the Shoalhaven region (Australian Bureau of 
Statistics 2015-2017b). 
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Figure 3- Illawarra and Shoalhaven census region by geographical area (Australian 
Bureau of Statistics 2015-2017a, 2015-2017b) 
 
Study 1, included a retrospective analysis of hospitalisations during the financial years 2015 to 
2017, for Illawarra Shoalhaven residents, aged 18 years and over, who presented to one of the 
nine Illawarra Shoalhaven Local Health District (ISLHD) hospitals: Coledale, Bulli, 
Wollongong, Port Kembla, Shellharbour, Kiama, David Berry, Shoalhaven and Milton-
Ulladulla, shown in Figure 4.  
 
Figure 4- Hospital locations for ISLHD  
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The participants included in Study 2, were aged 18 years and over, that had attended the 
Vascular Care Centre outpatient clinic in Wollongong, NSW, between 1 May 2018 and 28 
February 2019. The Vascular Care Centre is a private clinic, there are no public facilities run by 
the Illawarra Local Health District for vascular patients in NSW, except for diabetic foot clinics. 
All patients are referred to private rooms run by vascular surgeons. 
 
3.2 Study 1 
 
Study 1 was a retrospective cohort study undertaken in two stages (Figure 5). Stage 1 identified 
the study cohort, which included individuals prescribed apixaban, rivaroxaban or warfarin on 
one or more occasions in the Illawarra and Shoalhaven region. Stage 2 identified the hospitalised 
cohort, which included individuals hospitalised in the ISLHD for an ADE related to taking 
apixaban, rivaroxaban or warfarin.  
 








oral anticoagulants for 
financial years 2015/16 






for ADEs associated 
with oral anticoagulant 
in ISLHD for financial 
years 2015/16 and 
2016/17
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3.2.1 Stage 1- Study cohort 
 
3.2.1.1 Study population 
 
Stage 1 utilised PBS data obtained from the Department of Human Services Australia which 
provided information regarding subsidised medicines dispensed in Australia (Paige et al. 2015). 
The data included aggregated PBS prescription data about Illawarra and Shoalhaven residents, 
aged 18 and over, who had been dispensed one or more prescriptions for the oral anticoagulants, 
apixaban, rivaroxaban or warfarin, in each of the financial years 2015/16 and 2016/17, and 
across both financial years, based on date of dispensing and patient age at the end of each 
financial year. Switching between oral anticoagulant therapies is common practice (Hellfritzsch 
et al. 2016). For example, a Spanish study found 18.6% (n= 176/946) of patients with AF, who 
were prescribed warfarin, switched to NOAC therapy within 12 months of a prescription 
(Rivera-Caravaca et al. 2018). Without unit record data, the dates of any switching could not be 
quantified in this study. To ensure the size of the population at risk, was estimated as accurately 
as possible using aggregate data, the PBS request included information separately by financial 
year on the number of persons prescribed each NOAC individually, number prescribed any 
NOAC (apixaban or rivaroxaban) and number prescribed any anticoagulant (apixaban, 
rivaroxaban or warfarin). Patients who did not switch medications were therefore considered in 
the population at risk (denominator of hospitalisation rate) in each year they were dispensed that 
medication. Patients who switched medications (for example dispensed a NOAC and dispensed 
warfarin within a financial year), were counted in the population at risk of hospitalisation 
(denominator) for each drug for that year. Any hospitalisations were attributed in the 
hospitalisation rate (numerator of hospitalisation rate) for the drug which was being taken when 
hospitalised.  
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ADEs can occur within one month of initiation of treatment with an oral anticoagulant (Chen et 
al. 2016; McIlroy et al. 2018). The decision to include PBS data, based on a single supply, was 
to help capture every ADE resulting in hospitalisation while taking an oral anticoagulant. Unit 
record data would have provided information on the persistence of use of each medication, 
however because this level of data was costly and required long lead times to obtain, it was 
considered outside the scope of funding for this thesis.  
 
Data were not obtained for dabigatran because although it is approved for use in Australia, it was 
not subsidised by PBS for VTE during the study period. The PBS item codes for OACs available 
from Services Australia, listed in Table 6, combine VTE and AF indications under the same item 
code. For this reason, individuals prescribed apixaban, rivaroxaban or warfarin for AF were 
included in this research.  
 
Table 6- PBS item codes for oral anticoagulants 
PBS codes by indication apixaban rivaroxaban warfarin 













VTE or AF 02735Y 
02744K 
2268J 
AF * 02691P 
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3.2.1.2 Data analysis 
 
Descriptive statistical analysis was used to describe characteristics and prevalence rates 
calculated for Illawarra Shoalhaven individuals prescribed apixaban, rivaroxaban or warfarin 
across the study period:  
• Prevalence of apixaban, rivaroxaban and warfarin prescribed by sex, age and geographic 
region. 
• Prescription data by drug and by financial year. 
 
All statistical analyses were conducted using IBM Statistical Package for the Social Sciences 
(SPSS) version 26 (Murali 2019). 
 
3.2.2 Stage 2- Hospitalised cohort 
 
3.2.2.1 Study population 
 
The hospitalised cohort for Stage 2 were identified through a complex data extraction process 
and review of electronic medical records for patients who had been hospitalised in the ISLHD 
with a primary or secondary diagnosis of VTE, stroke or haemorrhage, while prescribed 
apixaban, rivaroxaban or warfarin.  
 
Patient data for Stage 2 were extracted from the Illawarra Health Information Platform (IHIP), a 
sophisticated non-identifiable data platform (University of Wollongong 2019). The extracted 
data included hospitalisations at ISLHD facilities, during financial years 2015/16-2016/17, with 
a primary or secondary diagnosis of VTE, haemorrhage or stroke, and hospitalisations for long 
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term oral anticoagulant use or anticoagulants causing ADEs in therapeutic use. Haemorrhagic 
events were categorised as either CRNMB (minor) or major haemorrhagic events as per the 
International Society of Thrombosis and Haemostasis definitions (International Society of 
Thromobosis and Haemostasis 2015). CRNMB was classified as a minor GI haemorrhage, such 
as epistaxis, haemoptysis, haematuria  or other minor haemorrhage (Kaatz et al. 2015). Major 
haemorrhage was characterised as haemorrhage into a critical site or a haemorrhage which  
required a blood transfusions (Kaatz et al. 2015). VTE ADEs included the first incidence of 
DVT and PE while taking an oral anticoagulant for any indication. Recurrent VTE was classified 
as a subsequent DVT or PE while taking oral anticoagulation. Ischaemic stroke ADEs were 
identified as transient ischaemic attacks or cerebral infarcts. 
 
ED presentations were extracted based on visit date and hospital admissions based on date of 
discharge. Diagnosis information was extracted using ICD-10-AM (9th edition) codes 
(Weatherspoon & Chattopadhyay 2013) for admitted patients and Systematized Nomenclature of 
Medicine- Clinical Terms (SNOMED CT) codes (Department of Health 2008) for ED 
presentations (Table 7). 
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Table 7- ICD-10-AM (9th edition) and SNOMED codes for DVT, PE, haemorrhage, stroke 
and circulating anticoagulant 
ICD-10-AM (9th edition) codes for 
haemorrhagic disorders and stroke  
SNOMED codes for haemorrhagic 
disorders and stroke 
D68.3- haemorrhagic disorders due to 
circulating anticoagulants 
R58- haemorrhage, not elsewhere classified 
K62.5- haemorrhage sphincter 
K13.7- haemorrhage mouth 
K22.8- haemorrhage oesophagus 
N32.8- haemorrhage bladder 
N39.9 haemorrhage uterine 
K92- haemorrhage bowel/stomach 
I60; I61; I62- haemorrhagic stroke 
I64- ischaemic stroke 
K25; K26; K27; K28; K29- gastro 
haemorrhage 
D62; J94.2; H113; H35.6; H43.1; N02; N95; 
R04- extracranial bleeding 
R31- unspecified haematuria 
191287000 - Haemorrhagic disorder due to 
circulating anticoagulant 
64779008- blood coagulation disorder 
75038005- cerebellar haemorrhage 
274100004- cerebral haemorrhage 
195176009- subdural haemorrhage 
95453001- subdural haematoma 
1386000- intracranial haemorrhage 
22490002- bleeding mouth 
1770902- bleeding oesophageal 
422504002- ischaemic stroke 
86276007- bleeding gums 
74474003- gastro haemorrhage 
266464001- haemorrhage rectum 
12063002- haemorrhage rectal 
197887003- haemorrhage bladder 
ICD-10-AM (9th edition) codes for VTE SNOMED codes for VTE 
I82.0 – Budd-Chiari Syndrome 
I82.1 – Thrombophlebitis migrans 
I82.2 – Embolism and thrombosis of Vena 
Cava 
I82.8 – Embolism and thrombosis of other 
specified veins 
I82.9 – Embolism and thrombosis of 
unspecified vein 
I80; I81.9 
I26.0 – Pulmonary embolism with mention of 
acute cor pulmonale 
I26.9 – Pulmonary embolism without mention 
of acute cor pulmonale 
I74- systemic embolism 
82385007- Budd-Chiara 
128053003- Deep vein thrombosis 
1748006- Thrombophlebitis of deep vein 
63363004- Superior vena cava syndrome 
371039008- Thromboembolic disorder 
42909802- Thromboembolism of vein 
234049002- Venous embolism 
111293003- Venous thrombosis 
309735004- Thrombosis lower limb 
59282003- Pulmonary embolism 
706870000- Acute PE 
713078005- PE on long-term anticoagulation 
74315008- Pulmonary microemboli 
233925004- Pulmonary thromboembolism  
ICD-10-AM (9th edition) codes for other  
Z92.1 long term anticoagulant use  
Y44.2; Y44.3- anticoagulants causing ADEs 
D68.5- primary thrombophilia 
D68.6- other thrombophilia 
 
After data extraction from IHIP, the pharmacist investigator (and Masters’ candidate) undertook 
a series of additional steps (Figure 6) to identify the hospitalised cohort (Stage 2 cohort) who had 
experienced an ADE, while prescribed apixaban, rivaroxaban or warfarin at time of presentation 
or admission to hospital. 
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Figure 6- Flow diagram for IHIP data extraction process and participant identification 
 
Patients needed to be residents of the Illawarra and Shoalhaven and aged 18 years and over for 
inclusion into the hospitalised cohort (Stage 2). Non-residents of the Illawarra and Shoalhaven 
were excluded. This research focused on unique ADEs and not on re-presentation to hospital for 
poor management of an ADE. This decision was made because of the evidence, primarily from 
the US, that approximately 17.9% of patients re-present to hospital at least once within 28 days 
of starting warfarin therapy due to poor management  (Hamar et al. 2018). Hence intra-hospital 
transfers and re-presentation to hospital within 28 days were excluded from Stage 2. Other 
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exclusions for Stage 2 included non-spontaneous events which were deemed to be expected side 
effects while taking oral anticoagulation therapy. For example, bruising following a fall or 
bleeding following procedures, such as a tooth extraction or colonoscopy. The rationale for these 
exclusions, were to explore spontaneous ADEs (Chen et al. 2016; Sembill et al. 2019) focusing 
on rates of ADEs and factors which contribute to intrinsically preventable ADEs, rather than 
external factors which could contribute to ADEs. In addition, malignancy was another exclusion 
criteria for stage 2 because of the evidence that malignancy significantly increases the 
pathophysiological risk of recurrent VTE by 13.2% (Thachil 2012) (Table 8). 
 
Table 8- Study 1 Stage 2 inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
• Resident Illawarra or Shoalhaven 
• 18 years and older 
• Hospitalisation for haemorrhage 
while taking apixaban, rivaroxaban 
or warfarin 
• Hospitalisation for VTE while 
taking apixaban, rivaroxaban or 
warfarin 
• Hospitalisation for ischaemic stroke 
while taking apixaban, rivaroxaban 
or warfarin 
• Re-presentations or readmissions 
after 28 days 
• Under 18 years 
• Re-presentations or readmissions 
within 28 days of discharge 
• Hospitalisation for haemorrhage 
within 24 hours following tooth 
extraction  
• Hospitalisation for haemorrhage 
following a mechanical fall 
• Hospitalisation for malignancy  
• Hospitalisation for post colonoscopy 
bleed 
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3.2.2.2 Data analysis 
 
Analysis for Stage 2 (hospitalised cohort) was conducted to investigate variance in demographic 
and clinical groups for patients presenting or admitted to ISLHD for ADEs by each financial 
year (2015/2016 and 2016/2017) and as combined years (2015-2017).  
 
Descriptive analyses (counts, means and percentages) were used to describe hospitalisations for 
ADEs among persons prescribed oral anticoagulants. The following patient subgroups were 
investigated to identify differences between oral anticoagulant ADEs: 
• region of residence (Illawarra and Shoalhaven) 
• type of hospitalisation (ED/admitted) 
• sex 
• age 
• length of stay (LOS) 
• potential contributing factors, including renal function, indication, comorbidities and INR 
 
Combined aggregated PBS data from Stage 1, and hospitalisation data from Stage 2, enabled 
estimation of rates of hospitalisations. Oral anticoagulant prescribing rates and ADE incidence 
rates were calculated using the mean of the rates at which unique individuals were prescribed 
each oral anticoagulant for each year, and are expressed as rates per 1,000 people prescribed per 
year. The following health service utilisation measures were used to investigate the ADEs for 
each oral anticoagulant: 
• total hospitalisations 
• hospitalisations by financial year  
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• type of hospitalisation (ED versus admission) 
• haemorrhagic events  
• VTE events for all indications  
• ischaemic stroke events for all indications  
 
The relative risk (RR) was calculated for the outcomes of ADEs for each oral anticoagulant in 
terms of VTE, haemorrhage and ischaemic stroke. The confidence interval (CI) used to quantify 
the uncertainty associated with estimates were calculated at the 95% level. Multivariate logistic 
regression analysis (Petrie & Sabin 2009) was used to model the probability of hospitalisation 
for ADEs (haemorrhage, VTE or ischaemic stroke), among residents taking each oral 
anticoagulant. The logistic regression model was used to estimate an unadjusted odds ratio (OR) 
for hospitalisation for an ADE among those taking NOACS compared to warfarin, then among 
those taking rivaroxaban compared to those taking apixaban. The model was then used to 
calculate an adjusted odds ratio (aOR) accounting for all covariates, sex, age and geographic 
region, which were all potential contributing factors for ADEs. No threshold for model entry was 
applied to ensure the model for each oral anticoagulant was adjusted for the same set of factors. 
Variance inflation factors were calculated to assess for multicollinearity between independent 
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3.3 Study 2 
 
Poor medication adherence and limited health literacy has been associated with inadequate 
anticoagulant control (Rolls et al. 2016). The second study was a small-scale pilot investigation 
into whether poor oral anticoagulant medication knowledge, understanding and adherence were 
present among those with recurrent VTE, whilst being prescribed a NOAC (apixaban or 
rivaroxaban) for treatment of VTE. The study consisted of patient interviews, which used a 
combination of four open-ended interview questions (Appendix 1) and the   
• Anticoagulation Knowledge Tool - a validated 20-item medication knowledge tool 
(Obamiro et al. 2016), and  
• Morisky, Green, and Levine (MGL) Adherence Scale, also known as the MAQ 
(Medication Assessment Questionnaire) (Morisky et al. 1986) a four-item Medication 
Adherence Questionnaire. 
Permissions were granted by the authors of the Anticoagulation Knowledge Tool and Morisky 
Medication Adherence Questionnaire (Appendix 2) to use these tools as part of the study. The 
20-minute interviews were conducted by the pharmacist researcher (Masters' candidate) for 
patients who had experienced a recurrent VTE, whilst prescribed a NOAC to treat a previous 
VTE and attended the Outpatient Vascular Care Centre, Wollongong between May 2018 and 
February 2019. These two stages of Study 2 are depicted in Figure 7.
Figure 7- Study 2 design 
Participant recruitment
Patients that attended the Vascular 
Care Centre for recurrent VTE while 
prescribed apixaban or rivaroxaban
Patient interviews
Thesis | Kerry Watts 
 




Participants were eligible for Study 2, if they were residents of the Illawarra and Shoalhaven, 
aged 18 years and over, and attended the Vascular Care Centre (Vascular Outpatient Clinic 
Cohort) for recurrent VTE while prescribed apixaban or rivaroxaban. Participants were required 
to be English speaking, because data collection tools were only available in English and the 
project budget did not include interpreter services. Eligible participants were required to have no 
documented cognitive impairment. More detailed inclusion and exclusion criteria for Study 2 
participants are described in Table 9. 
 
Table 9- Study 2 inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
• Resident Illawarra or Shoalhaven 
• 18 years and older 
• Attended vascular clinic for 
recurrent VTE whilst taking 
apixaban or rivaroxaban for VTE 
• English speaking 
 
• Non-resident of Illawarra or 
Shoalhaven 
• Under 18 years 
• Attended vascular clinic for recurrent 
VTE whilst prescribed other 
anticoagulation 
• Documented cognitive impairment 
 
All eligible patients that attended the Vascular Care Centre for review of a recurrent VTE, while 
taking apixaban or rivaroxaban, were invited to participate in the study and provided with the 
Patient Information Sheet (Appendix 3) and invited to complete the Patient Consent form 
(Appendix 4) during their attendance to the centre. The receptionist at the Vascular Care Centre 
provided invitations to all eligible patients. The receptionist was blinded to the aims of the study 
in order to eliminate any chance of selection bias by the pharmacist researcher (Masters’ 
candidate). The consent form provided contact information for the pharmacist researcher to call 
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and make an appointment for the telephone interview at a time which was convenient to the 
participant.  
 
3.3.2 Data collection 
 
An interview guide (Appendix 1) was used to structure the collection of data. Each telephone 
interview took an average of 20 minutes. The open-ended interview questions were primarily 
used to collect information about why the participant had attended the vascular clinic and to 
obtain a self-reported medical and medication history, while the medication knowledge tool 
(Obamiro et al. 2016) was used to collect information about the participant’s knowledge about 
the mechanism of action of the NOAC, why it was important to take the medication, and the 
consequences of missing doses or possible side effects. The medication adherence questionnaire 
(Morisky et al. 1986) was used to collect information about participant anticoagulant medication 
adherence behaviours.  
 
Each of the interviews were recorded on a digital audio recorder and transcribed verbatim. 
Results for the medication knowledge and adherence questionnaire were recorded as hard copies 
for each participant. 
 
3.3.3 Data analysis 
 
Descriptive statistical analyses were conducted on the scores obtained from participants’ 
completion of the validated anticoagulant medication knowledge tool (Obamiro et al. 2016). The 
knowledge tool was scored using a dichotomous scale with a score of ‘1’ for each correct or ‘0’ 
for an incorrect answer (Obamiro et al. 2016). A total of 20 questions were included, with 
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additional scores obtainable for question 4 regarding how the medicines are taken, question 6 
about why it is important to take the medicine exactly as prescribed by the doctor and questions 
18 and 19, which asks for three signs of side effect and three ways to reduce side effects 
(Appendix 3). The maximum score achievable, according to the validated tool, was 25, where 
the final scores were presented as a percentage of correct answers.  
 
Descriptive analysis was also used to investigate if medication adherence to NOACs, using the 
Morisky Medication Adherence Questionnaire (Morisky et al. 1986), was a contributor to 
recurrent VTE among the study participants . The questionnaire was scored using a dichotomous 
scale, answers of no scored ‘1’ and yes scored ‘0’. The maximum score achievable according to 
the Morisky scale was ‘4’. The final scores were rated from lowest adherence ‘1’ to highest 
adherence ‘4’ (Morisky et al. 1986). 
 
3.4 Ethical considerations 
 
Ethical approval to undertake Studies 1 and 2 were obtained from the combined University of 
Wollongong and ISLHD Human Research Ethics Committee, approval number 2017/493 
(Appendix 5). A Site-Specific Approval (SSA) was obtained to enable ethical research to be 
conducted within ISLHD (Appendix 6). 
 
Study 1 attained a waiver of patient consent from the ethics committee as a result of the large 
cohort. It was estimated that 5,000 hospitalisations would be included in the two-year 
retrospective study. This estimate was calculated from the number of hospitalisations attributed 
to haemorrhage or VTE as a principal or secondary diagnosis across the ISLHD. 
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A key ethical requirement for Study 2 of the research was to ensure that it was clearly 
communicated to participants that they could refuse or withdraw consent at any time, without 
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The findings for Study 1 and Study 2 are reported in detail below.  
 
4.1 Study 1 
 
This section will report on the findings from Study 1 of the research, based on the two stages 
described in the study design (Chapter 3).  
 
4.1.1 Stage 1- Study cohort 
 
4.1.1.1 Population cohort demographics 
 
The estimated residential population was 308,656 individuals, aged 18 years and over, for the 
four Illawarra SA3 regions (which accounted for 74.1% of the population cohort) and the one 
Shoalhaven SA3 region (25.9% of the population cohort) (Australian Bureau of Statistics 2016). 
The population cohort was 48.7% male and 51.3% female, and 74.5% of the population were 
aged under 65 years.  
 
4.1.1.2 Study cohort demographics 
 
According to the PBS data, 11,259 residents received one or more prescriptions for apixaban, 
rivaroxaban or warfarin in 2015/16, and 12,171 residents in 2016/17 (Table 10). The mean 
number of residents receiving one or more prescriptions for these oral anticoagulants per year 
was 11,715, or 3.8% (11,715/308,656) of the Illawarra and Shoalhaven population. 
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Males were prescribed oral anticoagulants at a higher rate than females, at 42.0 per 1,000 males 
per year, compared to 34.1 per 1,000 females per year (P<0.001, 95% CI 1.13-1.35) (Table 10). 
Prescribing rates of anticoagulants increased with age. Individuals aged under 65 years were 
prescribed oral anticoagulants at a rate of 9.6 per 1,000 people per year and individuals aged 80-
84 years at a prescribing rate of 192.6 per 1,000 persons per year. Individuals from the Illawarra 
region had a lower oral anticoagulant prescribing rate 36.3 per 1,000 persons per year than 
Shoalhaven residents 42.6 per 1,000 persons per year (P<0.001, 95% CI 0.78-0.93). 
 
Table 10- Study cohort population prescribing rates by demographics, 2015/16-2016/17 
 
a. Population aged 18 years and over 
b. The yearly counts are the mean of the counts from 2015/16 and 2016/17 




 Study cohort 
(Persons prescribed oral 
anticoagulants per year) 












Prescribing rates  
per 1,000 per year 
   N b (%) N (%) %  
Sex        
   Male  6,057 6,585 6,321 (54.0) 150,402 (48.7) 4.2 42.0 
   Female 5,202 5,586 5,394 (46.0)  158,254 (51.3) 3.4 34.1 
Age        
   <65 2,163 2,270 2,217 (18.9) 229,906 (74.5) 1.0 9.6 
   65-69 1,410 1,515 1,463 (12.5) 23,942 (7.8) 6.1  61.1 
   70-74 1,754 1,971 1,863 (15.9) 19,041 (6.2) 9.8 97.8 
   75-79 2,145 2,200 2,173 (18.5) 14,710 (4.8) 14.8 147.7 
   80-84 1,943 2,126 2,035 (17.4) 10,564 (3.4) 19.3 192.6 
   85+ 1,844 2,089 1,967 (16.8) 10,493 (3.4) 18.7 187.4 
Region       
   Illawarra 7,974 8,652 8,313 (71.0) 228,808 (74.1) 3.6 36.3 
   Shoalhaven 3,285 3,519 3,402 (29.0) 79,848 (25.9) 4.3 42.6 
Total 11,259 12,171 11,715 308,656  3.8 38.0 
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4.1.1.3 Oral anticoagulant prescriptions by year and demographics 
 
Prescribing rates by year 
 
Using the PBS data extracted for the two-year study period at least one prescription was 
dispensed to individuals, aged 18 years and over, as follows: 
• Apixaban: 2,038 persons in 2015/16 and 3,125 in 2016/17, mean of 2,582 per year. 
• Rivaroxaban: 3,809 persons in 2015/16 and 4,371 in 2016/17, mean of 4,090 per year. 
• NOAC total: 5,794 persons in 2015/16 and 7,369 in 2016/17, mean of 6,582 per year. 
• Warfarin: 5,912 persons in 2015/16 and 5,178 in 2016/17, mean of 5,545 per year. 
• NOAC or warfarin total: 11,259 in 2015/16 and 12,171 in 2016/17, mean of 11,715 per 
year. 
 
To quantify the PBS data for individuals dispensed at least one prescription, which does not 
account for switching of oral anticoagulant treatment within a financial year, the mean number 
of individuals dispensed NOACs and/or warfarin was 12,171, compared to 11,715 individuals 
dispensed either NOACs or warfarin. The mean number of individuals that switched their oral 
anticoagulant treatment from NOACs to warfarin, or vice versa, during 2015/16 and 2016/17 
was 412.  
 
Between 2015/16 and 2016/17 prescribing rates (residents with one or more prescription) for 
NOACs (apixaban or rivaroxaban) increased from 18.8 per 1,000 population per year to 23.9 per 
1,000 population per year (P<0.001, 95% CI 1.27-1.28). This contrasted with a decrease in the 
number of residents with one or more prescriptions for warfarin, from 19.2 per 1,000 population 
to 16.8 per 1,000 population per year (P<0.001, 95% CI 0.87-0.88) (Figure 8). During the same 
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period, prescribing rates for apixaban increased from 2,038 per 1,000 per year to 3,125 per 1,000 
population per year (53.3% increase) and rivaroxaban prescribing rates increased from 3,809 per 
1,000 population per year to 4,371 per 1,000 population per year (14.8% increase).  
 
Figure 8- Study cohort prescribing rate for NOACs and warfarin by financial year 
 
Prescribing rates by sex 
 
Table 11 shows prescription rates by sex and by oral anticoagulant. Higher prescribing rates 
were apparent for NOACs compared to warfarin, for both males and for females. Among males, 
NOACs were prescribed for 23.4 per 1,000 population per year compared to warfarin which was 
prescribed for 20.0 per 1,000 population per year (P<0.001, 95% CI 1.07-1.28). Among females, 
NOACs were prescribed for 19.3 per 1,000 population per year, compared to warfarin at 16.0 
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Table 11- Study cohort prescribing rate by oral anticoagulant and sex, 2015/16-2016/17 
 
Prescribing rates by age 
 
Prescribing rates increased with age for both NOACs and warfarin. NOAC prescribing rates 
were higher than for warfarin in the younger age groups (Figure 9); for example, for the under 
65-year age group (NOAC 6.9 per 1,000 population per year, warfarin 2.9 per 1,000 population 
per year, P<0.001, 95% CI 2.18-2.60). Warfarin was the most prescribed anticoagulant in 
persons aged over 80 years (including 80-84 and 85+), 115.6 per 1,000 population per year 





Apixaban Rivaroxaban NOACs Warfarin 
Sex N N a (Rate/ 
1,000/year) 
N a (Rate/ 
1,000/year) 
N b (Rate/ 
1,000/year) 
N a (Rate/ 
1,000/year) 
Male  150,402 1,370 (9.1) 2,195 (14.6) 3,524 (23.4) 3,009 (20.0) 
Female 158,254 1,212 (7.7) 1,895 (12.0) 3,058 (19.3) 2,537 (16.0) 
Total 308,656 2,582 (8.4) 4,090 (13.3)  6,582 (21.3) 5,545 (18.0) 
a. The prescribing rate is the average of the rates from 2015/16 and 2016/17. 
b. Counts of people prescribed each NOAC do not add to the total counts for all NOAC due to some people 
being prescribed more than one type of NOAC during the 2-year study period. 
c. Counts of people prescribed each oral anticoagulant do not add to the total counts for all oral 
anticoagulants due to some people being prescribed more than one type of NOAC or warfarin during the 
2-year study period 
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Prescribing rates by oral anticoagulant 
Apixaban Rivaroxaban NOACs Warfarin 
Age N N a  
(Rate/1,000/ 
year) 
N a  
(Rate/1,000/ 
year) 
N b  
(Rate/1,000/ 
year) 
N a  
(Rate/1,000/ 
year) 
   <65 229,906 447 (1.9) 1106 (4.8) 1576 (6.9) 670 (2.9) 
   65-69 23,942  363 (15.2) 582 (24.3) 925 (38.6) 589 (24.6) 
   70-74 19,041  428 (22.5) 687 (36.1) 1,097 (57.6) 840 (44.1) 
   75-79 14,710  480 (32.6) 723 (49.1) 1,172 (79.6) 1,093 (74.3) 
   80-84 10,564  449 (42.5) 557 (52.7) 981 (92.9) 1,140 (107.9) 
   85+ 10,493  415 (39.6) 435 (41.4) 831 (79.2) 1213(115.6) 
a. The yearly rate is the average of the rates from 2015/16 and 2016/17  
b. Counts of persons prescribed each NOAC do not add to the total counts for all NOAC due to some 
people prescribed more than one NOAC during the 2-year study period, and due to small cells being 
withheld for some age group by oral anticoagulant by region combinations in the aggregate PBS data. 
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Prescribing rates by region 
 
Overall, prescribing rates for oral anticoagulants were higher in the Shoalhaven region compared 
to the Illawarra region (Table 12). This pattern was consistent for NOACs, 22.8 per 1,000 
population per year in Shoalhaven, compared to 20.8 per 1,000 population per year in the 
Illawarra (P=0.040, 95% CI 1.00-1.20), and for warfarin 21.1 per 1,000 population per year in 
Shoalhaven compared to 16.9 per 1,000 population per year in the Illawarra (P<0.001, 95% CI 
1.14-1.36). The pattern of rivaroxaban prescribing by region was similar to the trend mentioned 
above, with Shoalhaven residents prescribed a rate of 15.7 per 1,000 population per year, 
compared to the Illawarra 12.4 per 1,000 population per year (P<0.001, 95% CI 1.16-1.39).  
 










Further comparisons between prescription data per year for apixaban, rivaroxaban and warfarin 









Prescribing rates by oral anticoagulant 
Apixaban 












N a  
(Rate/1,000/ 
year) Region N  
Illawarra 228,808  2,000 (8.7) 2,837 (12.4) 4,764 (20.8) 3,860 (16.9) 
Shoalhaven 79,848  582 (7.3) 1,253 (15.7) 1,818 (22.8) 1,685(21.1) 
a. The yearly rate is the average of the rates from 2015/16 and 2016/17  
b. Counts of persons prescribed each NOAC do not add to the total counts for all NOAC due to some 
people prescribed more than one NOAC during the 2-year study period, and due to small cells being 
withheld for some age group by oral anticoagulant by region combinations in the aggregate PBS data. 
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4.1.2 Stage 2- Hospitalised cohort 
 
4.1.2.1 Number of hospitalisations for adverse drug events 
 
In total, there were 9,432 presentations to ED or admissions to hospital for VTE, haemorrhage or 
stroke in ISLHD between 1 July 2015 and 30 June 2017 (Figure 10). Based on eMR notes, 551 
individuals were hospitalised on 585 occasions that met the study inclusion criteria. Of these, 90 
individuals presented to ED a total of 95 times, and 461 individuals were admitted on 490 
occasions. Overall, 6.2% (585/9,432) of hospitalisations for haemorrhage, VTE or stroke across 
the ISLHD were for individuals taking the oral anticoagulants apixaban, rivaroxaban and 
warfarin.  
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4.1.2.2 Overall hospitalised cohort demographics 
 
Males accounted for 52.6% of hospitalisations, compared to females 47.4%. However, males 
had a hospitalisation rate of 51.5 per 1,000 prescribed per year, compared to females 48.6 per 
1,000 prescribed per year, respectively (Table 13). The total number of hospitalisations 
increased with age, with 83.2% of the hospitalised cohort being 65 years of age or older. The 
average age of the hospitalised cohort was 75.2 years. Residents of the Illawarra contributed to 
the majority of hospitalisations (74.2%), consistent for both ED presentations (70.5%) and 
hospital admissions (74.5%). 
 
Table 13- Hospitalised cohort demographics by ED or admission, 2015/16-2016/17 
 ED  
presentations 
Admissions Total  
hospitalisations a 
Rate of hospitalisation  
per 1,000 prescribed 
per yearb  N (%) N (%) N (%) 
Sex     
   Male  47 (49.5) 260 (53.1) 307 (52.6) 48.6 
   Female 48 (50.5) 230 (46.9) 278 (47.4) 51.5 
Age     
   <65 21 (22.1) 77 (15.7) 98 (16.8) 44.2 
   65-69 6 (6.3) 34 (6.9) 40 (6.7) 27.3 
   70-74 15 (15.8) 52 (10.6) 67 (11.5) 36.0 
   75-79 19 (20.0) 94 (19.2) 113 (19.3) 52.0 
   80-84 18 (18.9) 96 (19.6) 114 (19.5) 56.0 
   85+ 16 (16.8) 137 (28.0) 153 (26.2) 77.8 
Region     
   Illawarra 67 (70.5) 367 (74.9) 434 (74.2) 52.2 
   Shoalhaven 28 (29.5) 123 (25.1) 151 (25.8) 44.4 
Total 95 (100.0) 490 (100.0) 585 (100.0)  
a. Hospitalisation counts are not adjusted for prescribing rates. 
b. The yearly rate is the average of the rates from 2015/16 and 2016/17  
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4.1.2.3 Hospitalised cohort demographics and length of stay by oral anticoagulant 
 
Individuals taking NOACs accounted for 48.4% of the hospitalised cohort (Table 14). There 
were 72 ADEs that required hospitalisation for individuals taking apixaban, 211 ADEs for 
individuals taking rivaroxaban and 302 ADEs for individuals taking warfarin.  
 
The average age for the hospitalised cohort was 78.1 years for individuals taking apixaban, and 
76.8 for those taking warfarin, and 72.1 years for those taking rivaroxaban. Residents of the 
Illawarra comprised 74.2% of total hospitalisations, a pattern which was evident for both 
NOACs and warfarin.  
 
The mean length of stay (LOS) for the admitted cohort was 7.3 days. Individuals taking NOACs 
had a mean LOS of 6.3 days, and those on warfarin 7.8 days (Table 14). The mean LOS for 
individuals admitted taking apixaban was 5.6 days and for rivaroxaban 6.9 days.  
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Table 14- Hospitalised cohort demographics by oral anticoagulant, 2015/16-2016/17 
 Apixaban Rivaroxaban NOACs Warfarin 
 N (%) Rateb N (%) Rateb N (%) Rateb N (%) Rateb 
Sex     
   Male  41 (56.9) 29.9 107 (50.7) 48.7 148 (52.3) 42.0 159 (52.6) 52.8 
   Female 31 (43.1) 25.6 104 (49.3) 54.9 135 (47.7) 44.1 143 (47.4) 56.4 
Age     
   <65 ˟ 51 (24.1) 46.1 ˟ ˟ 
   65-69 6 (8.3) 16.5 15 (7.1) 25.8 21 (7.4) 22.7 19 (6.3) 32.3 
   70-74 15 (20.8) 35.0 27 (12.8) 39.3 42 (14.8) 38.3 25 (8.3) 29.8 
   75-79 11 (15.3) 22.9 46 (21.8) 63.6 57 (20.1) 48.6 56 (18.5) 51.2 
   80-84 16 (22.2) 35.6 31 (14.7) 55.7 47 (16.6) 47.9 67 (22.2) 58.8 
   85+ 21 (29.2) 50.6 41 (19.4) 94.3 62 (21.9) 74.6 91 (30.1) 75.0 
Region     
   Illawarra 58 (80.6) 29.0 151 (71.6) 53.2 209 (73.9) 43.9 225 (74.5) 58.3 
   Shoalhaven 14 (20.4) 24.1 60 (28.4) 47.9 74 (26.1) 40.7 77 (25.5) 45.7 
Total ADEs 72 (12.3) 211 (36.1) 283 (48.4) 302 (51.6) 
Mean LOS (days) a 5.6 6.9 6.3 7.8 
a. admitted patients only 
b. The yearly rate is the average of the rates from 2015/16 and 2016/17 per 1,000 prescribed per year 
˟ suppressed cells <5 or to maintain confidentiality 
 
The number of hospitalisations for ADEs while taking NOACs increased by 20.4 percentage 
points across the two years, with a similar decrease in warfarin-related hospitalisations during 
the study period (Figure 11). 
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Figure 11- Hospitalised cohort prescribed NOACs and warfarin by financial year 
 
4.1.2.4 Rates of adverse events by oral anticoagulant 
 
The hospitalisation rate for ADEs among individuals prescribed oral anticoagulants during the 
two-year study period was 25.0 per 1,000 prescribed per year (r= (585/11,715/2) x 1,000). The 
hospitalisation rate for individuals prescribed NOACs was 21.5 per 1,000 prescribed per year, 
lower than the rate for warfarin of 27.2 per 1,000 prescribed per year (P<0.001, 95% CI 0.72-
0.86. Rivaroxaban was associated with a higher rate of hospitalisation 25.8 per 1,000 prescribed 
per year compared to apixaban 13.9 per 1,000 prescribed per year (P<0.001, 95% CI 1.70-2.03) 
(Table 15). 
Table 15- Rates for hospitalised adverse drug events by oral anticoagulant, 2015/16-
2016/17 
 Apixaban Rivaroxaban NOACs  Warfarin Total 
 N (%) N (%) N (%) N (%) N 
Hospitalisations (persons) a 72 (12.3) 211 (36.1) 283 (48.4) 302 (51.6) 585 
Prescriptions (persons)b 2,582 (22.3) 4,090 (35.3) 6,582 (56.9)c 5,545 (47.9) 11,715 
Rate d 13.9 25.8 21.5 27.2 25.0 
a. Hospitalisation counts are total counts in the two years 2015/16 and 2016/17 
b. Prescription counts are the average over 2015/16 and 2016/17 
c. Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral anticoagulants 
due to some people prescribed more than one oral anticoagulant during the 2-year study period and due to cell 
suppression.  
d. The yearly hospitalisation rate is the average hospitalisation rates over 2015/16 and 2016/17 per 1,000 
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The relative risk (RR) and odds ratio (OR) for hospitalisations differed between oral 
anticoagulants. Apixaban was associated with significantly less risk of hospitalisation for ADEs 
than warfarin (RR 0.51, 95% CI 0.40-0.66, P<0.0001) (Table 16). However, there was no 
significant difference between the risk of rivaroxaban and warfarin-related hospitalisation (RR 
0.95, 95% CI 0.80-1.12, P=0.53). There was no difference in risk of hospitalisation for 
rivaroxaban compared to warfarin (aOR 0.89, 95% CI 0.74-1.07, P=0.219), after adjusting for 
age, sex and region. Comparing the two NOACs, there was significantly more likelihood of 
hospitalisation associated with rivaroxaban than apixaban (aOR 2.06, 95% CI 1.57-2.71, 
P<0.0001). 
 
Table 16- Relative risk and odds ratio for oral anticoagulant-related hospitalisation 


















Non-adjusted OR (95% Cl) 0.43 (0.33-0.56) 0.80 (0.67-0.96) 0.66 (0.58-0.77) 1.86 (1.42-2.43) 
Significance (P)  P<0.0001* P= 0.017* P<0.0001* P<0.0001* 










* statistically significant when P=0.05 or less 
 
Variance inflation factors were calculated to assess for multicollinearity between independent 
variables in the regression model. There was no evidence of multicollinearity, as all values were 
close to 1 (VIF age = 1.001, VIF sex = 1.012 and VIF region = 1.005). The multivariate regression 
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4.1.2.5 Rates for adverse events by financial year 
 
In the 2015/16 financial year, individuals taking warfarin had a higher hospitalisation rate of 
30.4 per 1,000 prescribed per year, compared to NOACs, 19.0 per 1,000 prescribed per year 
(P<0.001, 95% CI 1.46-1.75) (Figure 12). In contrast, during the financial year 2016/17, 
hospitalisations were comparable between oral anticoagulants, with warfarin hospitalisations 
declined to 23.6 per 1,000 prescribed per year, while NOACs increased to 23.5 per 1,000 
prescribed per year (P=0.92, 95% CI 0.92-1.10).  
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 Apixaban Rivaroxaban NOACs Warfarin Total 
 N (%) N (%) N (%) a N (%) N 
2015/2016      
 Hospitalisations (persons) 26 (9.0) 84 (29.0) 110 (38.0) 180 (62.0) 290 
 Prescriptions (persons) 2,038(17.3) 3,809 (32.4) 5,794 (49.3) 5,912 (50.3) 11259 
   Rate per 1,000 per year 12.8 22.1 19.0 30.4 25.8 
2016/2017      
 Hospitalisations (persons) 46 (15.9) 127 (43.1) 173 (58.6) 122 (41.4) 295 
 Prescriptions (persons) 3,125(24.6) 4371 (34.5) 7,369 (58.1)    5,178 (40.9) 12171 
   Rate per 1,000 per year 15.0 29.1 23.5 23.6 24.2 
a. Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral 
anticoagulants due to some people prescribed more than one oral anticoagulant during the 2-year study 
period and due to cell suppression. 
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4.1.2.6 Rates for ED presentations versus hospital admissions 
 
ED presentation rates during the two-year study period averaged 4.1 per 1,000 people prescribed 
oral anticoagulants per year (n=95). The rates of ED presentations were considerably higher for 
individuals taking rivaroxaban 7.1 per 1,000 prescribed per year compared to apixaban 2.3 per 
1,000 prescribed per year (P<0.001, 95% CI 2.83-3.37) or warfarin 2.3 per 1,000 prescribed per 
year (P<0.001, 95% CI 2.83-3.37). In addition, five individuals taking rivaroxaban re-presented 
to ED with an additional anticoagulant-related ADE during the study period (8.6%; 5/58). 
Neither individuals taking apixaban or warfarin re-presented to ED during the study period 
(Table 17).  
 
The average admission rates for ADEs of oral anticoagulants were 20.9 per 1,000 prescribed per 
year (n=490). Admission rates were higher for individuals taking warfarin 25.0 per 1,000 
prescribed per year, compared to rivaroxaban 18.7 per 1,000 prescribed per year (P<0.001, 95% 
CI 1.22-1.46) and apixaban 11.6 per 1,000 (P<0.001, 95% CI 1.97-2.46). The readmission rates 
were 10.0% (6/60) for individuals taking apixaban, 7.2% (11/153) for rivaroxaban and 4.3% 
(12/277) for warfarin (Table 17).  
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Table 17- Rates of ED and admission by oral anticoagulant, 2015/16-2016/17 
2015-2017 Apixaban Rivaroxaban NOACs Warfarin Total 
 N (%) N (%) N (%) N (%) N (%) 
ED 
   1 presentation 
















Total ED 12 (12.6) 58 (61.1) 70 (73.7) 25 (26.3) 95 (100.0) 
Rate of ED presentation per 
1,000 people per year a b 
2.3 7.1 5.3 2.3 4.1 
Admitted 
   1 admission 
















Total Admitted 60 (12.2) 153 (31.2) 213 (43.5) 277 (56.5) 490 (100.0) 
Rate of admission per 1,000 
people per year a b 
11.6 18.7 16.2 25.0 20.9 
a. The yearly rate is the average of the rates from 2015/16 and 2016/17 (apixaban n=2582, rivaroxaban 
n=4,090, NOACs n=6582, warfarin n=5,545, total n=11,715) 
b. Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral 





4.1.2.7 Rates of haemorrhage adverse drug events 
 
Haemorrhagic events, the most common ADE requiring hospitalisation for all oral 
anticoagulants, were experienced by 18.1 per 1,000 prescribed per year (n=425) between 
2015/16 and 2016/17 (Figure 13). There was no significant difference between the rate of 
hospitalisation for haemorrhagic events between warfarin (20.0 per 1,000 prescribed per year) 
and rivaroxaban (18.4 per 1,000 prescribed per year) (P=0.06, 95% CI 0.99-1.19). Apixaban had 
a lower rate of hospitalisation for haemorrhagic events (10.1 per 1,000 prescribed per year) 
compared to warfarin (P<0.001, 95% CI 0.46-0.55). 
 
Individuals taking rivaroxaban had a comparable rate of CRNMB (14.9 per 1,000 prescribed per 
year) compared to warfarin (14.0 per 1,000 prescribed per year) (P=0.16, 95% CI 0.97-1.16) 
(Figure 13). Rates of CRNMB events for individuals taking apixaban however, were 
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substantially lower at 3.9 per 1,000 prescribed per year when compared to warfarin (P<0.001, 
95% CI 0.25-0.30.  
 
Individuals taking NOACs experienced a lower rate of major haemorrhage event (3.1 per 1,000 
prescribed per year) compared to warfarin (6.0 per 1,000 prescribed per year) (P<0.001, 95% CI 
0.47-0.56). These major haemorrhagic events for warfarin included intracranial haemorrhages at 
a rate of 1.8 per 1,000 prescribed per year and major GI haemorrhage at a rate of 3.1 per 1,000 
prescribed per year (Figure 13). The raw data for type of haemorrhage by drug is available in 
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 Apixaban Rivaroxaban NOACs Warfarin Total 
Adverse drug 
event 
N(Rate/1,000   
/year) a 









   GI  
   Haematuria 






















   Intracranial 
   GI 





















Total Haemorrhage 52 (10.1) 151 (18.5) 203 (15.4) 222 (20.0) 425 (18.1) 
a. The yearly rate is the average of the rates from 2015/16 and 2016/17 (apixaban n=2,582, rivaroxaban 
n=4,090, NOACs n=6582, warfarin n=5,545, total n=11,715) 
˟ suppressed cells <5 or to maintain confidentiality 
 
Figure 13- Haemorrhagic event hospitalisation rates by oral anticoagulant, 2015/16-
2016/17 
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Further statistical analysis into the location of other CRNMB events was prevented by small 
numbers reported for individuals taking NOACs. The table of haemorrhagic data including 
supressed cells can be viewed in Appendix 7. 
 
Overall, NOACs resulted in significantly less risk of haemorrhagic events than warfarin (RR 
0.77, 95% CI 0.64-0.93, P=0.0073), including after adjusting for sex, age and region (aOR 0.73, 
95% CI 0.60-0.89, P=0.002). These significant differences were only apparent for apixaban (RR 
0.51, 95% CI 0.38-0.78, P<0.0001) and not for rivaroxaban (RR 0.93, 95% CI 0.76-1.13, 
P=0.4599) (Table 18). However, when comparing NOACs, rivaroxaban use had a significantly 
higher risk of a haemorrhagic event than apixaban (aOR 2.06, 95% CI 1.50-2.84, P<0.0001) 
(Table 18). 
 
Table 18- Relative risk and odds ratio for total haemorrhage adverse drug events by oral 
anticoagulant 
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4.1.2.8 Rates of venous thromboembolic adverse drug events 
 
VTE treatment failure were experienced by 8.7% of people with oral anticoagulant ADE-related 
hospitalisations (Figure 14). Individuals taking rivaroxaban had a higher rate of VTE-related 
hospitalisations (4.0 per 1,000 prescribed per year) compared to apixaban (1.2 per 1,000 
prescribed per year) (P<0.001, 95% CI 3.05-3.64) and warfarin (1.2 per 1,000 prescribed per 
year) (P<0.001, 95% CI 3.05-3.64). In addition, between 2015-2017, rivaroxaban accounted for 
a higher rate of recurrent VTE events requiring hospitalisation (3.4 per 1,000 prescribed per 
year), compared to warfarin (0.8 per 1,000 prescribed per year) (P<0.001, 95% CI 3.89-4.64). 
The rate for apixaban has not been included due to small numbers and the need for cell 
suppression. 
Thesis | Kerry Watts 
 
Page | 81  
 
  
Figure 14- VTE hospitalisation rates by oral anticoagulant, 2015/16-2016/17 
 
 
The relative risk and odds ratio for VTE ADEs differed between oral anticoagulants. A 
comparison of NOACs and warfarin, found that NOACs had a significantly higher relative risk 
(RR 2.46, 95% CI 1.31-4.62, P= 0.0150) and odds ratio (OR 2.15, 95% CI 1.15-4.03, P= 0.017) 
than warfarin. When adjusted for age, sex and region there was no longer a statistical difference 
between the classes of oral anticoagulant (Table 19). The odds ratio of hospitalisation for VTE 
while prescribed rivaroxaban was significantly higher than both apixaban (OR 3.44, 95% CI 
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˟ 28 (3.4) ˟ 9 (0.8) ˟  
a. The yearly rate is the average of the rates from 2015/16 and 2016/17 (apixaban n=2,582, rivaroxaban 
n=4,090, NOACs n=6,582, warfarin n=5,545, total n=11,715) 
b. Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral 
anticoagulants due to some people prescribed more than one oral anticoagulant during the 2-year 
study period.  
˟ suppressed cells <5 or to maintain confidentiality 
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1.44-8.21, P=0.005) and warfarin (OR 2.96, 95% CI 1.04-5.63, P=0.001) (Table 19). This 
pattern was consistent after adjustment by sex, age and region. The relative risk of recurrent 
VTE was significantly higher for rivaroxaban versus warfarin (RR 4.22, 95% CI 1.99-8.93, 
P=0.0002). In contrast, there was no difference in risk of hospitalisation for VTEs between 
individuals prescribed apixaban and warfarin.  
 
Table 19- Relative risk and odds ratio for VTE adverse drug events by oral anticoagulant  


















Non-adjusted OR (95% Cl) 0.86 (0.33-2.27) 2.96 (1.56-5.63) 2.15 (1.15-4.03) 
P= 0.017* 
3.44 (1.44-8.21) 
Significance (P)  P= 0.7619 P=0.001* P= 0.005* 










Relative Risk (RR) for recurrent VTE ADE by oral anticoagulant 
RR (95% Cl) 
Significance (P) 
˟ 4.22 (1.99-8.93) 
P=0.0002 
˟ ˟ 
*statistically significant when P<0.05  
˟ supressed cells 
 
4.1.2.9 Rates of ischaemic stroke adverse drug events 
 
The rate of ischaemic stroke treatment failure requiring hospitalisation, while taking an oral 
anticoagulant, was 4.3 per 1,000 prescribed per year (Figure 15). Individuals taking warfarin had 
a higher rate of ischaemic stroke (5.3 per 1,000 prescribed per year) compared with those taking 
apixaban (2.9 per 1,000 prescribed per year; P<0.001, CI 1.121-1.232) or rivaroxaban (3.1 per 
1,000 prescribed per year; P<0.001, CI 0.761-0.826). The raw data for type of stroke by drug is 
available in Appendix 9 (Table 31). 
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 Apixaban Rivaroxaban NOACs Warfarin Total 















Ischaemic stroke 15 (2.9) 25 (3.1) 40 (3.0) 59 (5.3) 99 (4.2) 
a. The yearly rate is the average of the rates from 2015/16 and 2016/17 (apixaban n=2582, rivaroxaban 
n=4090, NOACs n=6582, warfarin n=5545, total n=11,715) 
b. Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral 
anticoagulants due to some people prescribed more than one oral anticoagulant during the 2-year study 
period.  
 
Figure 15- Ischaemic stroke hospitalisation rates by oral anticoagulant, 2015-16/2016-17 
 
Based on the relative risk and odds ratio, individuals taking NOACs (apixaban and rivaroxaban) 
had a significantly lower risk of ischaemic stroke events when compared to warfarin (RR 0.57, 
95% CI 0.38-0.85, P=0.0061) (Table 20). These findings were consistent after adjusting odds 
ratios for age, sex and region. There was no difference in risk of ischaemic stroke between 
apixaban and rivaroxaban. 
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Table 20- Relative risk and odds ratio for ischaemic stroke adverse drug events by oral 
anticoagulant 






































* statistically significant when P<0.05 
 
4.1.2.10 Summary of findings 
 
To summarise the findings, the plot of aOR demonstrates that individuals prescribed rivaroxaban 
had a significantly higher risk of a VTE event and no difference in haemorrhagic ADE when 
compared to warfarin (Figure 16). There was no difference in VTE risk between apixaban and 
warfarin, however apixaban had significantly less risk of haemorrhage and ischaemic stroke. 
 
 
Figure 16- Adjusted odds ratio plot of adverse drug events 
0.1 1 10
VTE apixaban versus warfarin
VTE rivaroxaban versus warfarin
Haemorrhage apixaban versus warfarin
Haemorrhage rivaroxaban versus warfarin
Ischaemic stroke apixaban versus warfarin
Ischaemic stroke rivaroxaban versus warfarin






0.57 (0.36-0.92)  
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4.1.3 Stage 2 Hospitalised cohort contributing factors 
 
Results relating to renal function, indication and comorbidities as contributing factors for ADEs 
were only available for the admitted patient cohort. The ED cohort was excluded because of 
limited and inconsistent documentation of medication histories.  
 
4.1.3.1 Renal function 
 
Moderate to severe renal impairment were common among the hospitalised cohort for 
individuals taking warfarin (54.9%) and NOACs (55.2%) (Table 21). A total of nine individuals 
admitted to hospital for ADEs while taking oral anticoagulants did not have their renal function 
assessed at admission.  
 
Table 21- Admitted cohort renal function by oral anticoagulant, 2015/16-2016/17 
 Apixaban Rivaroxaban NOACs Warfarin Total 




N (%) N (%) N (%) 
   >80mL/min (normal) 
   50-79mL/min (mild) 
   30-49mL/min (mod) 
   <30mL/min (severe) 


























Total a 61 (100.0) 154 (100.0) 215 (100.0) 275 (100.0) 490 (100.0) 
˟ suppressed cells <5 or to maintain confidentiality 
a. Cells may not appear to add to totals due to suppressed cell values 
 
Further descriptive analysis of rivaroxaban admissions found that when measured on admission 
to hospital, 32 individuals admitted for ADEs with an AF indication had moderate or severe 
renal impairment. It should be acknowledged that this may not have been the renal function at 
point of prescribing, but concomitant acute illness could have precipitated a decline in renal 
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function. Nevertheless, moderate or severe renal impairment reduces the elimination of NOACs 
and the risk of accumulation of the anticoagulant could contribute to haemorrhagic ADEs. The 
recommended dose for rivaroxaban in AF for this cohort is 15mg once daily. In 37.5% (n=12) of 
cases the prescribed doses of rivaroxaban exceeded the maximum dose, including 20mg once 




AF was the most common indication among individuals admitted to hospital for ADEs (71.0%) 
(Table 22), compared to VTE (20.2%) (Table 22). Other unlicensed indications, including 
mechanical mitral valve, were found in 10.2% (n= 22/215) of all NOAC-related admissions 
during the study period (Table 22). 
 
Table 22- Indications for admitted cohort by oral anticoagulant, 2015/16-2016/17 
 Apixaban Rivaroxaban NOACs Warfarin Total 



















Total a 61 154 215 275 490 
˟ suppressed cells <5 or to maintain confidentiality 




Hypertension, cardiac disease, hyperlipidaemia and diabetes were common co-morbidities 
among the individuals admitted to hospital with anticoagulant-related ADEs. Individuals with a 
history of bleeding/anaemia were admitted for ADEs while taking NOACs (apixaban 18.2% or 
rivaroxaban 14.7%), compared with warfarin (11.4%) (Table 23). In total, 34.5% of individuals 
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hospitalised taking apixaban had experienced a stroke as a co-morbid condition, compared to 
26.6% taking warfarin or 13.3% taking rivaroxaban. Only 3.7% of admissions for individuals 
taking NOACs and 5.1% of individuals taking warfarin had a diagnosis of thrombophilia as a co-
morbidity. Population-adjusted rates were not calculated for comorbidities because individuals 
had more than one documented comorbidity. A pairwise comparison of comorbidities is 
available in Appendix 10 (Table 32). 
 
Table 23- Comorbidities for admitted cohort by oral anticoagulant, 2015/16-2016/17 
 Apixaban Rivaroxaban NOACs Warfarin Total 
 N (%) N (%) N (%) N (%) N (%) 
Medical history       
Cardiac (CF, IHD) 29 (47.5) 47 (30.5) 76 (35.3) 111 (40.3) 187 (38.2) 
HTN 44 (72.1) 83 (53.9) 129 (60.0) 148 (53.8) 235 (47.9) 
DM 22 (36.1) 37 (24.0) 59 (27.4) 83 (30.2) 142 (28.9) 
Hyperlipid/hypercholesterol 19 (31.1) 48 (31.2) 67 (31.2) 87 (31.6) 154 (31.4) 
Stroke (CVA, TIA) 19 (31.1) 19 (12.3) 38 (17.7) 70 (25.4) 108 (22.0) 
PVD ˟ ˟ 8 (3.7) 25 (9.1) 33 (6.7) 
Bleeds/Anaemia 10 (16.4) 21 (13.6) 31 (14.4) 30 (10.9) 61 (12.4) 
Thrombophilia ˟ ˟ 8 (3.7) 14 (5.1) 22 (4.5) 
Total a 61 (100.0) 154 (100.0) 215 (100.0) 275 (100.0) 490(100.0) 
˟ suppressed cells <5 or to maintain confidentiality 
a. Cells may not appear to add to totals due to suppressed cell values 
 
 
4.1.3.4 International Normalised Ratio 
 
The INR was found to be in therapeutic range in less than half of individuals taking warfarin 
who had been admitted to hospital for ADEs (42.9%) (Table 24). Even though 10 (3.6%) of the 
individuals admitted for ADEs while taking warfarin, did not have their INR taken, 30.5% were 
in the supratherapeutic range and 22.9% were in the subtherapeutic range. The average INR for 
the cohort taking warfarin on admission to hospital for ADE s was 3.17. The highest recorded 
INR level taken was 13.2 and the lowest was 0.9.  
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Table 24- INR results of admitted cohort taking warfarin, 2015/16-2016/17 
 
 Warfarin 
INR N (%) 
Supratherapeutic >3 
Therapeutic 2-3 
Subtherapeutic <2   
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4.2 STUDY 2- SMALL SCALE PILOT STUDY 
 
4.2.1 Demographic characteristics of small-scale pilot study participants 
 
Between May 2018 and February 2019, seventeen patients were invited to participate in Study 2. 
These patients had presented to the Vascular Care Centre with recurrent VTE while taking 
NOACs for treatment or prophylaxis of VTE. The target sample size was 15 participants, to pilot 
the knowledge and adherence tools in such a specific patient cohort. Eight patients declined the 
invitation to be included in the study. The reasons for declining included medical issues or no 
reason given. A total of nine participants were included in the study (Table 25). Of these nine 
participants who had experienced recurrent VTE, seven had been taking apixaban and two were 
taking rivaroxaban. The average age of participants was 68 years. It should be acknowledged 
that the findings from this small study sample size is not generalisable. This study does however, 
provide a descriptive investigation of the knowledge and adherence of this previously unstudied 
patient cohort, drawing attention to the need and importance of a larger sample study and 
thereby attract funding to undertake this research. 
 
Table 25- Participant demographic and clinical characteristics 
Demographic characteristics Participants (n=9) 
Male n (%) 5 (55%) 
Female n (%) 4 (45%) 
Mean age in years (age range) 68 (55-77) 
Number taking apixaban 7 
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4.2.2 Oral anticoagulation knowledge tool 
 
Overall, the average score for anticoagulant knowledge among the Study 2 participants was 
58.5%. All of the participants knew the name, indication and dosing frequency of their oral 
anticoagulant. All the participants recognised that it was not appropriate to stop taking their 
medication once they felt better; or to take more of the anticoagulant than prescribed by their 
doctor. All of the participants also knew that they needed to inform other health professionals 
about their use of anticoagulants. The majority of participants (88.9%) recognised that it was not 
acceptable to double the dose, if a dose was missed and that it was important to take NOACs at 
the same time each day. Fewer of the participants (66.7%) understood that they needed to 
consult with their doctor before taking vitamin and/or herbal supplements with their 
anticoagulants.  
 
Less than half of the study participants understood how the medicine works in the body (33.3%), 
and why it was important to take NOACs exactly as directed (44.4%). A prompt from Question 
4 regarding what time of day the NOAC was taken indicated both participants taking 
rivaroxaban did not take this medication with food. Only two participants (22.2%) knew the 
most important side effects of their anticoagulants, while only one participant knew that skipping 
a dose of a NOAC could worsen their condition or could list ways to reduce their risk of 
experiencing side effects. None of the participants had any changes to their regular medications 
prior to the recurrent VTE.  
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Table 26- Item-level analysis of 20 item anticoagulation knowledge questions  




What is the name of your anticoagulant medicine?   9 (100.0) 1 
Why has your doctor prescribed this medicine?   9 (100.0) 2 
How many times a day do you need to take this medicine?   9 (100.0) 4 
Is it important that all health care practitioners you see know 
that you are taking this medicine? 
  9 (100.0) 16 
Is it appropriate to stop taking this medicine once you feel 
better? 
  9 (100.0) 10 
Is it safe to take anti-inflammatory medicines like ibuprofen 
while you are taking this medicine? 
  9 (100.0) 11 
Is there any benefit in taking more of this medicine that your 
doctor has told you to take? 
  9 (100.0) 13 
Is it necessary to inform a surgeon, dentist or other health 
professional that you are taking this medicine before 
undergoing a procedure? 
  9 (100.0) 15 
For how long do you need to take this medicine (3, 6 months, 
life-long)? 
  8 (88.9) 5 
Is it acceptable to double the next dose of this medicine if 
you miss a dose? 
  8 (88.9) 8 
Is it acceptable to take this medicine at different times as 
long as you take it on the required days? 
  7 (77.8) 7 
Will drinking too much alcohol increase the risk of side 
effects with this medicine? 
  7 (77.8) 14 
Is it safe to take vitamin supplements and herbal medicines 
with this medicine without consulting your doctor? 
  6 (66.7) 12 
Why is it important to take this medicine exactly as your 
doctor has told you? 
  4 (44.4) 6 
How does the medicine work in the body?   3 (33.3) 3 
What is the most important side effect of this medicine?   2 (22.2) 17 
Is it possible that skipping one dose of this medicine could 
worsen your condition? 
Three signs of side effects that you should watch for                                      






Three things you can do to reduce your risk to side effect  
What is the best step to take if you accidently take too much 









^Validated knowledge tool approved for use on 30th May 2018 (Obamiro et al. 2016). 
 
4.2.3 Oral anticoagulant adherence questionnaire 
 
In response to the four-item Morisky Medication Adherence Questionnaire, all participants were 
adherent in taking their NOAC medication, and did not stop taking their medication either when 
Thesis | Kerry Watts 
 
Page | 92  
 
they were feeling better or when they were feeling worse (Table 27). A lack of adherence was 
found among four participants who had forgotten to take their NOAC, and three had been 
careless at times about taking their oral anticoagulant.  
 
Table 27- Item-level analysis of anticoagulation adherence questions 
Question N (%) correct  
Do you ever forget to take your oral anticoagulant? 5 (55.5) 
Are you careless at times about taking your oral anticoagulant? 6 (66.7) 
When you feel better do you sometimes stop taking your oral anticoagulant? 9 (100.0) 
Sometimes when you feel worse do you stop taking your oral anticoagulant? 9 (100.0) 
*Score low-high; yes=0; no=1  
^Adherence questionnaire approved for use 31st May 2018 (Morisky et al.) 
 
Table 28 shows that all study participants that experienced recurrent VTE had medium to high 
adherence scores for taking their NOACs.  
 
Table 28- Anticoagulation adherence questionnaire scores 
Adherence score N (%) 
1= low adherence 0 (0.0) 
2-3= medium adherence 5 (55.0) 
4= high adherence 4 (45.0) 
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The main aim of this thesis was to compare the rate and risk of hospitalisation for oral 
anticoagulant-related ADEs among individuals taking NOACs (apixaban and rivaroxaban) and 
warfarin over a 2-year period in the Illawarra Shoalhaven region. The key findings from this 
thesis were that individuals taking NOACs had a significantly lower risk of any ADE compared 
to warfarin and a lower risk of total haemorrhagic ADE requiring hospitalisation. Notably, the 
risk of total haemorrhagic ADEs was comparable for individuals taking rivaroxaban or warfarin, 
but was significantly less for individuals taking apixaban. A sub-analysis of the total 
haemorrhagic ADEs identified that the hospitalisation rates for CRNMB, including minor GI 
haemorrhage, were lower for apixaban and comparable for rivaroxaban and warfarin. The risk of 
major haemorrhagic events was lower for apixaban, when compared to warfarin, but the risk was 
comparable for apixaban and rivaroxaban. The most important finding from this thesis is that 
individuals taking rivaroxaban had a significantly higher risk of hospitalisation for a VTE ADE 
compared to warfarin and apixaban. In contrast, individuals taking warfarin had a higher risk of 
being hospitalised for an ischaemic stroke ADE compared to the NOACs. 
 
It is estimated that total ADEs account for between 4.2 and 30.0% of hospital admissions in the 
USA and Canada and between 5.7 and 18.8% of admissions in Australia (Sultana et al. 2013). 
The current study found that oral anticoagulants contributed to 6.2% (n=585/9432) of ISLHD 
hospitalisations for ADEs (haemorrhage, VTE or ischaemic stroke). 
 
In total, individuals taking the two NOACs studied (apixaban and rivaroxaban) experienced a 
significantly lower risk of hospitalisation for ADEs when compared to warfarin (RR 0.79, 95% 
CI 0.67-0.92). These findings concur with results from a South Australian study which found a 
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significantly higher risk of hospital admissions for individuals taking warfarin compared to 
NOACs (RR 3.42, 95% CI 2.41-4.87) (Roberts et al. 2016). Although fewer individuals were 
prescribed rivaroxaban in this study (13.3 per 1,000 population per year), than warfarin (18.0 per 
1,000 population per year), the hospitalisation rates were comparable (aOR 0.89, 95% CI 0.74-
1.07). Individuals taking rivaroxaban had a significantly higher risk of hospitalisation compared 
with apixaban (aOR 2.06, 95% CI 1.57-2.71). Furthermore, individuals taking apixaban had a 
lower risk of hospitalisation compared to warfarin (aOR 0.45, 95% CI 0.34-0.58). Potentially, a 
reason for lower risk of hospitalisation for apixaban compared to rivaroxaban and warfarin could 
be that after only gaining PBS listing in 2015, apixaban prescribing was still gaining momentum. 
 
Risk factors for hospitalisation while taking oral anticoagulants in the Illawarra Shoalhaven 
 
Across the two-year study period NOAC prescribing increased from 20.8 per 1,000 population 
per year (2015/16) to 22.7 per 1,000 population per year (2016/17) and there was a reduction in 
warfarin prescribing (from 19.2 per 1,000 population per year to 16.8 per 1,000 population per 
year). Concurrently, hospitalisations for individuals taking NOACs increased by 20.4 percentage 
points between 2015/16 (38.6%) and 2016/17 (59.0%), while hospitalisations for individuals 
taking warfarin decreased by 20.4 percentage points (from 61.4% to 41.0%). Further studies 
need to assess if this trend continues.  
 
While more Shoalhaven residents were prescribed apixaban, rivaroxaban or warfarin when 
compared to Illawarra residents, the unadjusted hospitalisation rate was lower for Shoalhaven 
residents in comparison to the Illawarra residents. The higher prescribing rate and lower 
hospitalisation rate for Shoalhaven residents may be due to various differences between the 
Shoalhaven region and the Illawarra region, some of which may include: more prescribing of 
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dabigatran; more individuals taking oral anticoagulants visiting private hospitals or hospitals 
outside the studied local health district; better patient counselling and medication management to 
avoid ADEs; or more ADEs potentially managed outside of hospital. However, this would 
require further research which incorporates ADEs managed in other facilities, for example 
private hospitals and general practice, and qualitative research into medication management. 
 
The current study found prescribing and hospitalisation rates for individuals taking oral 
anticoagulants increased substantially with age. For instance, 83.2% of individuals hospitalised 
for ADEs, while taking oral anticoagulants, were aged 65 years and over. Although the 
percentage of hospitalisations for individuals less than 80 years of age was higher while taking 
the two NOACs (61.5%) than warfarin (47.7%), due to higher prescribing rates of NOACs in 
this cohort, the rate of hospitalisation remained lower for NOACs than warfarin (21.5 per 1,000 
prescribed per year and 27.2 per 1,000 prescribed per year, respectively). In addition, the 
percentage of hospitalisations remained lower for individuals aged over 80 years taking NOACs 
compared to warfarin (38.5% and 52.3%, respectively). Although individuals aged over 80 years 
were previously underrepresented in clinical trials when comparing the ADEs of NOACs to 
warfarin (Deitelzweig et al. 2019), a recent observational study concluded that NOACs were 
safe in this older cohort  (Monelli et al. 2019). These findings may in part support the findings of 
the current study.   
 
Existing literature has found that males have a higher risk of AF (Kannel & Benjamin 2008) and 
higher annual incidence rate of VTE compared to females (males 130 per 100,000; females 110 
per 100,000) (Heit 2015). This may in part explain why findings from this current study found 
that substantially more males were prescribed oral anticoagulation (42.0 per 1,000 population 
per year) compared to females (34.1 per 1,000 population per year).  
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Hospitalisation rate of haemorrhagic ADEs between oral anticoagulants  
 
Haemorrhage, including minor and major haemorrhage, is the most common ADE reported with 
oral anticoagulant use (Khan & Datta 2015) and the findings from this research are consistent 
with the literature. Haemorrhage accounted for the majority of ADEs for apixaban (72.2%), 
rivaroxaban (71.6%) and warfarin (73.5%) which were relatively consistent for the different oral 
anticoagulants. These appear to be in contrast to those of an Australian observational study, 
which found that NOACs were associated with a decrease in hospitalisations for bleeding events 
compared to warfarin (incidence rate ratio 2.89; 95% confidence interval 2.02-4.12; p < 0.001) 
(Roberts et al. 2019). In terms of minor haemorrhage or CRNMB events, the current study found 
individuals taking NOACs (apixaban and rivaroxaban) also had comparable risk of 
hospitalisation for total CRNMB events when compared to warfarin (RR 1.12, 95% CI 0.96-
1.29). These findings are also in contrast to the international literature which suggests that 
NOACs have lower CRNMB events in comparison to warfarin (Adam et al. 2013; Es et al. 2014; 
Rollins et al. 2014). However, in the current study individuals taking apixaban had lower rates of 
CRNMB hospitalisations (7.7 per 1,000 prescribed per year), compared to individuals taking 
rivaroxaban (14.9 per 1,000 prescribed per year) or warfarin (14.0 per 1,000 prescribed per 
year), which support the evidence that apixaban is likely to cause fewer bleeding events 
compared to rivaroxaban (Bahit et al. 2017; Dawwas et al. 2019)  and warfarin (Bahit et al. 
2017; Dawwas et al. 2019).   
 
Individuals with a haemorrhagic history or previous anaemia were hospitalised for CRNMB 
events while taking NOACs (14.4%) more than individuals taking warfarin with the same 
history (11.4%). These results are consistent with the HAS-BLED calculator which aims to 
assess individual haemorrhagic risk, including haemorrhagic history and predisposition, for 
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example anaemia, as important risk factors (Lip et al. 2011). However, this prediction tool was 
implemented in 2010 before the introduction of NOACs and includes labile INR and alcohol 
consumption as part of the tool, which are not affected by NOACs and may need to be reviewed. 
This finding is further supported by studies, which found higher rates of GI haemorrhage with 
NOAC use (Abraham et al. 2015; Granger et al. 2011), and contraindications for NOAC use in 
patients with clinically significant active haemorrhage or history of GI haemorrhage 
(McCaughan 2017). These findings suggest that NOACs may not be the best choice for 
individuals with a haemorrhagic history or anaemia and require further larger-scale studies to 
investigate the safety of NOAC use in individuals with a haemorrhagic history.  
 
This study found individuals taking apixaban had the lowest rate of hospitalisations for major 
haemorrhagic ADEs (2.3 per 1,000 prescribed per year), compared to individuals taking warfarin 
(6.0 per 1,000 prescribed per year) or rivaroxaban (3.5 per 1,000 persons per year). This result 
mirrors a prospective UK cohort study of 150,454 participants , which found that individuals 
taking apixaban  had a decreased risk of major bleeding events (aHR 0.66, 95% CI 0.54 to 0.79 
and aHR 0.66, 95% CI 0.54 to 0.79, respectively), compared with warfarin (Vinogradova et al. 
2018). However, the current study findings that individuals taking rivaroxaban are less likely to 
be hospitalised for major haemorrhagic ADEs, compared to warfarin are inconsistent with a 
USA study which found no significant differences in major haemorrhagic events for the two 
anticoagulants (OR 0.98, 95% CI 0.83-1.17) (Lip et al. 2016). While it is not clear what has 
contributed to this inconsistency, the findings do support a Phase III clinical trial (Van Es et al. 
2014) , which found that intracranial haemorrhage, a major haemorrhagic event, is less likely to 
occur with NOACs compared to warfarin (0.5 per 1,000 prescribed per year and 1.8 per 1,000 
prescribed per year, respectively).  
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Hospitalisation rate of VTE Treatment failure between oral anticoagulants  
 
Treatment failure is a recognised risk of all medications, including NOACs (McIlroy et al. 
2018). The current research found a higher rate of VTE treatment failure for individuals 
prescribed oral anticoagulants, 2.2 per 1,000 prescribed per year, compared to the reported 
annual incidence of VTE of 1.5 per 1,000 people per year (P<0.001, 95% CI 1.34-1.60) (Stevens 
et al. 2019). The rate of VTE in this study would be expected to be higher than the national 
average because the study focused on VTE ADEs for all oral anticoagulant indications. It is 
worth noting however, that these direct comparisons are difficult to interpret, given the 
heterogeneous nature of study participants for the many different studies which have 
investigated oral anticoagulant related outcomes, the different methodologies used and the many 
different outcome measures and definitions for these outcomes (e.g. bleeding events) 
(EINSTEIN DVT investigators 2010; EINSTEIN PE investigators 2012; Streiff et al. 2016).  
 
The research of Lutsey et al (2019) was the first published investigation of the rate of VTE while 
treated for a non-VTE indication, for example AF, and supports the model of treatment failure 
utilised in this study. Lutsey et al, investigated 117,912 AF patients and found a lower hazard 
ratio of VTE among those taking apixaban compared to warfarin (HR 0.51, 95% CI 0.39-0.68), 
but a similar risk of VTE incidence among those taking rivaroxaban compared to warfarin (HR 
1.01, 95% CI 0.87-1.19) (Lutsey et al. 2019). Individuals taking rivaroxaban in the current study, 
were twice as likely to be hospitalised for a VTE ADE compared to warfarin, regardless of 
whether they were prescribed for VTE treatment/prophylaxis or AF. However, unlike 
rivaroxaban, there were no significant differences in risk of hospitalisation for VTE ADEs 
among those taking apixaban compared to warfarin. Although these findings are supported by 
previous evidence (Streiff et al. 2016) the number of individuals included in this current study 
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taking apixaban were small and need to be taken into consideration when interpreting the results. 
These findings may suggest that apixaban and warfarin are less likely than rivaroxaban to result 
in VTE ADEs, which would make them more favourable options for the treatment and 
prevention of VTE. However, this would require further research on a much larger scale, given 
the small number of individuals taking apixaban in this study (n=72) which in the majority of 
cases was prescribed for AF, rather than the treatment or prevention of VTE.  
 
Studies have concluded no difference in rates of VTE recurrence between NOACs and warfarin 
(Castellucci et al. 2014; Streiff et al. 2016). However, this research found that individuals taking 
rivaroxaban had a significantly higher rate of hospitalisation for recurrent VTE events (3.4 per 
1,000 prescribed per year), compared to individuals taking warfarin (0.8 per 1,000 prescribed per 
year) (RR 4.22, 95% CI 1.99-8.93). These significant findings potentially suggest that warfarin 
could be the safer option in the management of VTE compared to rivaroxaban, and comparable 
to apixaban. 
 
NOACs are popular alternatives to warfarin for the primary prevention of strokes (Paschke et al. 
2020) and are recommended in Australia as first line for stroke prevention in at risk patients with 
non-valvular AF (Brieger et al. 2018). The findings from this research, suggest that individuals 
taking rivaroxaban and apixaban were found to be significantly less likely to be hospitalised for 
ischaemic stroke when compared to warfarin (aOR 0.57, 95% CI 0.36-0.92 and aOR 0.41, 95% 
CI 0.27-0.76, respectively). These results support the evidence that lower risks of stroke have 
been reported with individuals taking apixaban compared to warfarin (Granger et al. 2011; Yao 
et al. 2016). However, they are in contrast to the evidence which suggests similar stroke risks for 
rivaroxaban and warfarin (Shpak et al. 2018; Yao et al. 2016) and they also conflict with a recent 
retrospective German observational study of 837,430 patients, which found that individuals 
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taking NOACs had a higher risk of stroke (HR 1.32; CI 1.29–1.35) compared to vitamin K 
antagonists (Paschke et al. 2020). These inconsistent results may potentially be due to the current 
study investigating ischaemic stroke ADEs for individuals taking oral anticoagulants for all 
indications rather than being limited to AF. These discrepancies warrant further investigation 
using unit record data to account for duration of oral anticoagulant treatment, switching oral 
anticoagulation, adherence, comorbid conditions and drug interactions. 
 
Potential contributing factors to hospitalisation for ADEs 
 
It is well documented that renal impairment increases the risk of anticoagulant-related ADEs, 
including ischaemic stroke and haemorrhage (Heine et al. 2018) and that individuals with severe 
renal impairment and comorbidities should be prescribed warfarin (Amin et al. 2017; Heine et al. 
2018; Hillis & Crowther 2014). It is not surprising therefore, that 41.1% (n=113) of individuals 
hospitalised while taking warfarin, in the current study, had moderate to severe renal 
impairment. It is surprising however, that even though NOACs require dose adjustments in renal 
impairment and are contraindicated in severe renal impairment (Vandiver et al. 2014), 26.1% 
(n=56) of hospitalised individuals taking NOACs, in the current study, had moderate to severe 
renal impairment on admission. Furthermore, the dose of rivaroxaban was not appropriately 
reduced to account for the severity of renal impairment in 37.5% (n=12) as per dosage 
recommendations at the time of the study. These dosage recommendations however, were 
revised in June 2020, and now suggest that rivaroxaban is contraindicated in severe renal failure  
(i.e. CrCl <15mL/min rather than CrCl <30mL/min) (Weber et al. 2019). Even though the 
investigation into suboptimal dose management of NOACs in renal impairment was limited by 
small numbers and requires further investigation, the findings suggest that there is a need for 
monitoring of renal function on commencement and throughout treatment with NOACs.  
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Prescribing medication for an unlicensed indication is considered a risk factor for ADEs, since 
the safety and efficacy of the drug for these indications remains unknown (Bellis et al. 2014). 
There is a paucity of existing evidence relating to the use of NOACs for individuals with 
prosthetic heart valves, which is currently not recommended (Vandiver et al. 2014). 
Nevertheless, 10.2% (n=22) of admitted individuals taking NOACs in the present study had 
documented unlicensed indications for their use, which included treatment for mitral valve 
disorders, ischaemic heart disease, peripheral vascular disease and stroke prevention without a 
history of AF. These findings may be based on very small numbers, however they suggest that 
hospitalisations for apixaban, when prescribed for unlicensed indications, resulted in more 
hospitalisations for ADEs 13.1% (n= 8), than when prescribed for the licensed VTE indications 
3.3% (n=2). These findings therefore suggest that off-label use of NOACs may be a contributing 
factor to ADE hospitalisations, which is why NOAC prescribing should be limited by approved 
indications and monitored for potential drug interactions until further research can support the 
safety and efficacy of NOACs in these patient cohorts.  
 
This study found that the most common comorbidities among individuals taking apixaban, 
rivaroxaban or warfarin, hospitalised for ADEs, included diabetes mellitus, hyperlipidaemia 
(hypercholesterolaemia) and peripheral vascular disease. Despite NOACs not being 
recommended for use in individuals living with thrombophilia, which increases the risk of 
clotting events (Signorelli et al. 2016), thrombophilia was found to be a comorbid condition in 
eight individuals taking NOACs (3.6%), seven of whom were admitted for VTEs. While it needs 
to be acknowledged that these numbers are small, it is concerning that NOACs are being 
prescribed when contraindicated.  
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Exploring medication adherence and knowledge as a contributing factor to VTE treatment 
failure for outpatients 
 
To date, poor adherence to warfarin has been well documented (Kearon et al. 2016; Thachil 
2012) and it is recognised that therapeutic INR control can be used as a surrogate measure of 
adherence (Shikdar & Bhattacharya 2019). The evidence suggests that supratherapeutic INR 
levels (INR >3), which was the case for 30.5% (n=84/275) of individuals admitted to hospital in 
Study 1, increases the risk of haemorrhagic ADEs. This proportion of individuals with 
supratherapeutic INRs is almost twice that reported in a study undertaken by Nelson et al (2015), 
which found that 16% of 9433 participants had supratherapeutic INRs. Importantly however, 
Nelson et al’s study (2015) investigated INR control in patients treated for non-valvular AF over 
a six-month period and included both hospitalised and non-hospitalised patients. The current 
study also found that 22.9% (n=63/275) of individuals admitted to hospital (Study 1) had 
subtherapeutic INRs <2, which increases the risk of experiencing ADEs and treatment failure. 
These subtherapeutic proportions were similar to those cited in the Nelson et al study (2015).  
Unlike warfarin, there is no simple biochemistry measure or monitoring system which can be 
used to measure adherence to NOACs. This is of concern given that a UK cohort study 
(n=36,652) found that non-adherence for individuals taking NOACs for AF was lower when 
compared to individuals taking warfarin (rivaroxaban OR 0.61, 95% CI 0.58-0.65; apixaban OR 
0.57, 95% CI 0.54-0.61) (Banerjee et al. 2020). In the absence of being able to monitor NOAC 
adherence in study 1, the Master’s candidate was only able to collect self-reported self-
adherence data in study 2, a very small pilot study.  To the best of her knowledge this is the first 
Australian study to investigate vascular outpatients that have presented with treatment failure 
based on a recurrence of their VTE. The findings, which need to be considered carefully given 
the small number of participants, suggest that knowledge of NOACs appears to have not 
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improved from previous Australian research (Obamiro et al. 2016) and medium or high 
medication adherence may still result in recurrent VTE.  
 
Patient knowledge and understanding of oral anticoagulation has been found to have the greatest 
impact on adherence (Clarkesmith et al. 2017; Smet et al. 2018). The average score for the 
Anticoagulant Knowledge Tool (AKT) used in this study was 58.5%, which was similar to the 
results for the 50 patients (62.0%) who were included in the Australian study which validated the 
tool (Obamiro et al. 2016). Participant knowledge was sound relating to basic information 
including drug name, indication and dosing frequency of their oral anticoagulant. Their lack of 
knowledge related to understanding how the NOACs work (33.3%), potential side effects 
associated with taking NOACs (22.2%) and the impact of missing a NOAC dose (11.1%). The 
knowledge deficits found in this study are unknown, and may be attributed to a lack of health 
literacy or inadequate information provided to patients by health care professionals as suggested 
in the literature  (Smet et al. 2018).  
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Population-based research is required to understand the impact of a novel therapy in a patient 
population that is far more generalisable than the selected patient populations used in clinical 
trials. This thesis found, compared to warfarin, those taking rivaroxaban had a higher risk of 
hospitalisation for a VTE ADE and a similar risk of haemorrhage. Individuals taking apixaban 
were found to have a similar risk of VTE events compared to warfarin, but a lower risk of 
haemorrhage and ischaemic stroke. The use of rivaroxaban and apixaban resulted in similar risks 
of ischaemic stroke events requiring hospitalisation. Furthermore, comorbidities such as 
thrombophilia, renal impairment and medication knowledge were found to be factors which need 
to be considered when prescribing and selecting oral anticoagulant therapy. Selecting the 
optimal oral anticoagulation needs to be made on an individual basis, understanding the 
indication being treated and potential patient risk factors.  
 
Overall, this research is an example of the important implications of population-level evidence. 
In the post-marketing approval of NOACs, several observational studies have been published, 
however, the limitations and methodological challenges associated with the different types of 
real-world studies must be considered carefully when interpreting the findings (Camm & Fox 
2018). This thesis complements existing studies, providing an insight into treatment outcomes 
based on population-level evidence, rather than evidence from systematic reviews and meta-
analyses and clinical trial data which often exclude older people and those living with co-
morbidities.  
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7. IMPLICATIONS FOR CLINICAL PRACTICE 
 
The higher hospitalisation rates of VTE ADEs for individuals taking rivaroxaban compared to 
warfarin found from this study are a concern for patient safety. These findings warrant further 
research and may ultimately require a review of the therapeutic guidelines and the 
recommendation for NOACs as first-line therapy for VTE management. In the interim, 
prescribers need to be informed about the risks of related VTE ADEs and encouraged to actively 
assess adherence or request a pharmacist review by way of a home medication review, for 
example. 
 
These findings highlight the importance of consumer medication information and adherence 
monitoring from prescribing clinicians and pharmacists. The key recommendations for clinicians 
and pharmacists in helping to reduce the risk of ADEs requiring hospitalisation for individuals 
taking oral anticoagulants are to ensure adequate counselling, emphasising why it is important to 
take NOACs as prescribed, and the significance of missing doses. Pharmacists, in particular, 
should plan to re-emphasise the importance of adherence at each prescription refill. A further 
recommendation for clinicians and pharmacists is to promote an individualised approach to 
NOAC selection rather than the marketed ‘one drug fits all’ attitude, focusing on bleeding risk, 
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8. STENGTHS AND LIMITATIONS 
 
The main strengths of this research were the population-level data and the in-depth 
individualised patient review of hospitalisations across a Local Health District which included 
admissions across nine hospitals for study 1 in particular. This allowed the researcher to provide 
a more detailed analysis of hospital admissions and ED presentations for individuals taking oral 
anticoagulation. In addition, the patient centred interview and individual survey completion 
(Study 2) provided pilot study data regarding knowledge and adherence to NOACs.  
 
In addition to these strengths however, the research had several limitations: 
 
1. The study did not include dabigatran because it is not subsidised by the PBS for use in 
VTE which would have skewed the findings by all indications. 
2. This study did review potential drug interactions, including NSAIDs, macrolides, aspirin, 
clopidogrel, fish oil, but could not provide any useful analysis at this level, with limited 
individual data to assess the impact of these potential interactions on ADEs.  
3. The study was undertaken in one Local Health District, within a regional area of NSW. 
The region is representative of Australia in terms of socio-demographics, but we cannot 
be sure that it is representative of prescribing patterns. In addition, we only have data on 
hospitalisations at public hospitals and are missing admissions to private hospitals or 
admissions to hospitals outside the region, e.g., Queanbeyan, South Eastern Sydney. 
4. The PBS item codes included in this study did not incorporate the subset code level. PBS 
item codes are further divided into subset codes to allow for differentiation between 
prescribed indications or criteria. For example, the rivaroxaban PBS item code included 
in this study was 2268J. However, rivaroxaban prescription data could be analysed by 
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retrieving the subset PBS data by indication: VTE 4099, 4132, 4268 and AF 4269. The 
use of PBS subset codes would allow for population-adjusted rates for treatment failure 
of VTE ADEs while taking oral anticoagulation for VTE only or stroke ADEs when 
taking oral anticoagulation for AF only. The subset codes were not applied to this study 
because warfarin prescribing does not have subset codes and could therefore not be 
analysed at this level. 
5. The use of aggregate data for this study did not include exposure time. The PBS data was 
retrieved based on individuals receiving one or more prescription of an oral anticoagulant 
within each financial year, and across the two-year study period. There were no start and 
end dates included in the data retrieval, therefore it was assumed that the drug was 
prescribed to each individual for the entire year. By using aggregate annual data, it was 
not possible to more finely adjust for time at risk within a financial year, therefore we 
assumed a patient was at risk of an ADE for the entire financial year during which their 
anticoagulant was dispensed. This may have overestimated the time at risk for some 
patients and therefore may have under-estimated the rate of hospitalisation compared to 
persons hospitalised per year at risk. While this assumption may under-estimate the 
hospitalisation rate for all oral anticoagulants, if patients more commonly switch from 
NOACs to warfarin, and spend less time on NOACs, then it would have more impact on 
under-estimation of NOAC hospitalisation rates. In addition, the data did not account for 
non-adherence which may differ by oral anticoagulant, and may limit the generalisability 
of the findings. A larger study would benefit from unit record PBS data, which include 
start and end dates, prescribed amounts and changes in oral anticoagulation, as well as 
longitudinal hospital data, which could be adjusted for additional comorbid risk factors. 
A prospective study on a sample of patients would be required to incorporate measures of 
medication adherence.  
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6. Adherence was not measured as part of Study 1. The PBS data did not identify whether 
individuals regularly filled their prescriptions or continued treatment for each year of the 
study. 
7. Apixaban became subsidised for use by the PBS in 2015, and unlike warfarin and 
rivaroxaban, was only just starting to be prescribed at the beginning of the study period. 
This may have contributed to smaller prescription numbers and hospitalisations for 
apixaban related VTE ADEs, which may impact on the generalisability of the results.  
8. The study outcomes were limited to ADEs resulting in hospitalisation and cannot provide 
an insight into the number of ADEs that did not require hospitalisation, including 
individuals that died at home, or provide comparative patient factors, such as medication 
history, indication for use and renal function for non-hospitalised patients in the 
community setting. The results of this study therefore, may underrepresent the true extent 
of anticoagulant related ADEs occurring outside of hospitals and currently being 
managed by GPs or vascular consultants in clinics. 
9. IHIP data extraction enabled the review of all hospitalisations in ISLHD according to 
documented admission ICD-10 AM (9th edition) and ED SNOMED codes. There is 
potential for human error in coding these files, which may have resulted in a lack of 
retrieval of ADEs, in particular SNOMED codes relevant for ED presentations. Coding 
quality is much higher in the admitted patient data where qualified coders translate 
documentation to ICD-10-AM (9th edition) codes and up to 100 diagnoses can be 
recorded compared to up to 4 in the ED SNOWMED coded record.  
10. The Master’s candidate (pharmacy researcher) reviewed eMR documentation which 
differed in quality between site and the health professional that entered the data, allowing 
for potential human error for omitted documentation, which may have resulted in a lack 
of or unnecessary inclusion into the data analysed. Furthermore, screening for medication 
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history and reason for admission from eMR may have resulted in under-reporting issues 
by the treating physician or reporting bias by the researcher. In addition, this method was 
very time-consuming. However, the potential confounder of researcher bias was 
mitigated by a randomised review of all included results, including medication history, 
indication for use, reason for admission and renal function, for 10% of the hospitalised 
cohort by a second health professional researcher, which agreed with the results. 
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9. PROPOSED FUTURE RESEARCH 
 
There are several future studies either as an expansion to this research or based on the findings 
of this research that require further investigation: 
 
1. A larger-scale study, including a larger population for apixaban, is required to allow for 
further analysis of ADEs of NOACs compared to warfarin in the Australian community. 
2. To investigate VTE events while taking oral anticoagulation managed outside of hospital 
settings.  
3. Efficacy of aspirin use in comparison to oral anticoagulation for post-operative VTE 
prophylaxis. 
4. A larger scale NOAC knowledge and adherence study is required to investigate the 
















Thesis | Kerry Watts 
 
Page | 111  
 
 
10. FUNDING AND CONFLICTS OF INTEREST 
 
This thesis received a total of $2,200 to obtain Pharmaceutical Benefit Scheme (PBS) 
prescription data to enable population rate comparisons. The ISLHD Vascular Research Fund 
contributed $1,200 and the University of Wollongong Science, Medicine and Health Higher  
Degree Research student allocation provided the remaining $1,000.  
There were no conflicts of interest involved in this thesis. 
  
Thesis | Kerry Watts 
 




Abraham, N, Singh, S, Alexander, G, Heien, H, Haas, L, Crown, W & Shah, N 2015, 
‘Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and 
warfarin: population based cohort study’, British Medical Journal, vol. 350, p. h1857. 
Adam, S, McDuffie, J, Lachiewicz, P, Ortel, T & Williams Jr, J 2013, ‘Comparative 
effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients 
having total hip or knee replacement’, Annals of Internal Medicine, vol. 159, no. 4, pp. 
275-89. 
Agnelli, G, Buller, H, Cohen, A, Curto, M, Gallus, A, Johnson, M, Masiukiewicz, U, Pak, R, 
Thompson, J, Raskob, G & Weitz, J 2013, ‘Oral apixaban for the treatment of acute 
venous thromboembolism’, Journal of New England, vol. 369, no. 9. 
Agnelli , G, Buller , HR, Cohen , A, Curto , M, Gallus , AS, Johnson , M, Masiukiewicz , U, Pak 
, R, Thompson , J, Raskob , GE & Weitz , JI 2013, ‘Oral apixaban for the treatment of 
acute venous thromboembolism’, New England Journal of Medicine, vol. 369, no. 9, pp. 
799-808. 
Ahmad, Y & Lip, G 2012, ‘Stroke prevention in atrial fibrillation: concepts and controversies’, 
Current cardiology reviews, vol. 8, no. 4, pp. 290-301. 
American Society of Clinical Oncology 2019, Venous thromboembolism prophylaxis and 
treatment in cancer patients clinical practice guidelines. 
AMH 2018, Australian Medicines handbook, Adelaide. 
Amin, A, Keshishian, A, Trocio, J & Vo, L 2017, ‘Effectiveness and safety of apixaban, 
dabigatran and rivaroxaban compared to warfarin among non-vavlvular atrial fibrillation 
patients in the US Medicare population’, Journal of the American College of Cardiology, 
vol. 69, no. 11, p. 316. 
Anderson, I & Cifu, A 2018, ‘Management of bleeding in patients taking oral anticoagulants’, 
JAMA, vol. 319, no. 19, pp. 2032-3. 










Bahit, M, Lopes, R, Wojdyla, D, Held, C, Hanna, M, Vinereanu, D, Hylek, E, Verheugt, F, 
Goto, S, Alexander, J, Wallentin, L & Granger, C 2017, ‘Non-major bleeding with 
apixaban versus warfarin in patients with atrial fibrillation’, Heart, vol. 103, no. 8, pp. 
623-8. 
Banerjee, A, Benedetto, V, Gichuru, P, Burnell, J, Antoniou, S, Schilling, R, Strain, W, Ryan, R, 
Watkins, C, Marshall, T & Sutton, C 2020, ‘Adherence and persistence to direct oral 
anticoagulants in atrial fibrillation: a population-based study’, Heart, vol. 106, no. 2, pp. 
119-26. 
Basaran, O, Basaran, N, Cekic, E, Altun, I, Dogan, V, Mert, G, Mert, K, Akin, F, Soylu, M, 
Sancar, K & Biteker, M 2015, ‘Prescription patterns of oral anticoagulants in nonvalvular 
atrial fibrillation (proper study)’, Clinical and Applied Thrombosis/Hemostasis, vol. 0, 
no. 0, p. 1076029615614395. 
Thesis | Kerry Watts 
 
Page | 113  
 
Bauer, K 2013, ‘Pros and cons of new oral anticoagulants’, American Society of Haemotology 
ASH Education Book, vol. 2013 no. 1, pp. 464-79. 
Bellis, J, Kirkham, J, Nunn, A & Pirmohamed, M 2014, ‘Adverse drug reactions and off-label 
and unlicensed medicines in children: a prospective cohort study of unplanned 
admissions to a paediatric hospital’, British Journal of Clinical Pharmacology, vol. 77, 
no. 3, pp. 545-53. 
Beyer-Westendorf, J, Förster, K, Pannach, S, Ebertz, F, Gelbricht, V, Thieme, C, Michalski, F, 
Köhler, C, Werth, S, Sahin, K, Tittl, L, Hänsel, U & Weiss, N 2014, ‘Rates, 
management, and outcome of rivaroxaban bleeding in daily care: results from the 
Dresden NOAC registry’, Blood, vol. 124, no. 6, pp. 955-62. 
Brieger, D, Amerena, J, Attia, J, Bajorek, B, Chan, K, Connell, C, Freedman, B, Ferguson, C, 
Hall, T, Haqqani, H, Hendriks, J, Hespe, C, Hung, J, Kalman, J, Sanders, P, 
Worthington, J, Yan, T & Zwar, N 2018, ‘National Heart Foundation of Australia and the 
Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the 
diagnosis and management of atrial fibrillation 2018’, Heart, Lung and Circulation, vol. 
27, no. 10, pp. 1209-66. 
Burness, C & Perry, C 2014, ‘Rivaroxaban: A review of its use in the treatment of deep vein 
thrombosis or pulmonary embolism and the prevention of recurrent venous 
thromboembolism’, Drugs, vol. 74, no. 2, pp. 243-62. 
Camm, A & Fox, K 2018, ‘Strengths and weaknesses of ‘real-world’ studies involving non-
vitamin K antagonist oral anticoagulants’, Open Heart, vol. 5, no. 1, p. e000788. 
Castellucci, L, Cameron, C, Le Gal, G, Rodger, M, Coyle, D, Wells, P, Clifford, T, Gandara, E, 
Wells, G & Carrier, M 2014, ‘Clinical and safety outcomes associated with treatment of 
acute venous thromboembolism: A systematic review and meta-analysis’, JAMA, vol. 
312, no. 11, pp. 1122-35. 
Chen, E, Diug, B, Bell, J, mc Namara, K, Dooley, M, Kirkpatrick, C, McNeil, J, Caughey, G & 
Ilomäki, J 2016, ‘Spontaneously reported haemorrhagic adverse events associated with 
rivaroxaban and dabigatran in Australia’, Therapeutic advances in drug safety, vol. 7, no. 
1, pp. 4-10. 
Chin, PKL & Doogue, MP 2016, ‘Long-term prescribing of new oral anticoagulants’, Australian 
Prescriber, vol. 39, no. 6, pp. 200-4. 
Clarkesmith, D, Pattison, H, Khaing, P & Lane, D 2017, ‘Educational and behavioural 
interventions for anticoagulant therapy in patients with atrial fibrillation’, The Cochrane 
database of systematic reviews, vol. 4, no. 4, pp. CD008600-CD. 
Health 2014, Medication safety and quality VTE prevention, by Clinical Excellence 
Commission, Australian Government. 
Connell , N & Butera, J 2015, ‘Attending physician attitudes toward choice of oral anticoagulant 
for the treatment of venous thromboembolism.’, R I Med J vol. 98, no. 7, pp. 32-6. 
Dawwas, G, Brown, J, Dietrich, E & Park, H 2019, ‘Effectiveness and safety of apixaban versus 
rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding 
events in patients with venous thromboembolism: a retrospective population-based 
cohort analysis’, The Lancet Haematology, vol. 6, no. 1, pp. 20-38. 
Deitelzweig, S, Keshishian, A, Li, X, Kang, A, Dhamane, A, Luo, X, Balachander, N, 
Rosenblatt, L, Mardekian, J, Pan, X, Nadkarni, A, Di Fusco, M, Garcia Reeves, A, Yuce, 
H & Lip, G 2019, ‘Comparisons between oral anticoagulants among older nonvalvular 
atrial fibrillation patients’, Journal of the American Geriatrics Society, vol. 67, no. 8, pp. 
1662-71. 
Department of Health 2019, Database for adverse events notifications- medicines, 
<https://apps.tga.gov.au/PROD/DAEN/daen-report.aspx>. 
Thesis | Kerry Watts 
 
Page | 114  
 
EINSTEIN DVT investigators 2010, ‘Oral rivaroxaban for symptomatic venous 
thromboembolism’, New England Journal of Medicine, vol. 363, no. 26, pp. 2499-510. 
EINSTEIN PE investigators 2012, ‘Oral rivaroxaban for the treatment of symptomatic 
pulmonary embolism’, New England Journal of Medicine, vol. 366, no. 14, pp. 1287-97. 
Electronic Medicines Compendium 2018, Xarelto 20mg film-coated tablets, 
<https://www.medicines.org.uk/emc/medicine/25586>. 
Elsebaie, M, van Es, N, Langston, A, Buller, H & Gaddh, M 2019, ‘Direct oral anticoagulants in 
patients with venous thromboembolism and thrombophilia: a systematic review and 
meta-analysis’, Journal of Thrombosis and Haemostasis, vol. 17, no. 4, pp. 645-56. 
eMIMS 2016, Rivaroxaban, dabigatran, apixaban, 2016 edn, NSW Health via CIAP, 04/04/17. 
Es, Nv, Coppens, M, Schulman, S, Middeldorp, S & Büller, HR 2014, ‘Direct oral 
anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: 
evidence from phase 3 trials’, Blood, vol. 124, no. 12, pp. 1968-75. 
Franchini, M & Mannucci, P 2016, ‘Direct oral anticoagulants and venous thromboembolism’, 
European Respiratory Review, vol. 25, no. 141, pp. 295-302. 
Generalova, D, Cunningham, S, Leslie, S, Rushworth, G, McIver, L & Stewart, D 2018, ‘A 
systematic review of clinicians’ views and experiences of direct-acting oral 
anticoagulants in the management of nonvalvular atrial fibrillation’, British Journal of 
Clinical Pharmacology, vol. 84, pp. 2692–703. 
Goddard, M 2014, ‘How the pharmaceutical benefits scheme began’, Medical Journal Australia, 
vol. 201, no. 1, pp. 23-5. 
Granger, C, Alexander, J, McMurray, J, Lopes, R, Hylek, E, Hanna, M, Al-Khalidi, H, Ansell, J, 
Atar, D, Avezum, A, Bahit, M, Diaz, R, Easton, D, Ezekowitz, J, Flaker, G, Garcia, D, 
Geraldes, M, Gersh, B, Golitsyn, S, Goto, S, Hermosillo, A, Hohnloser, S, Horowitz, J, 
Mohan, P, Jansky, P, Lewis, B, Lopez-Sendon, J, Pais, P, Parkhomenko, A, Verheugt, F, 
Zhu, J & Wallentin, L 2011, ‘Apixaban versus warfarin in patients with atrial 
fibrillation’, New England Journal of Medicine, vol. 365, no. 11, pp. 981-92. 
Gray, D 2014, Doing research in the real world, 3 edn, SAGE, London. 
Gurol, E 2018, ‘Secondary stroke prevention in atrial fibrillation’, Stroke, vol. 49, no. 6, pp. 
1315-7. 
Hamar, B, Coberley, C, Pope, J, Cottrill, A, Verrall, S, Larkin, S & Rula, E 2018, ‘Effect of 
post-hospital discharge telephonic intervention on hospital readmissions in a privately 
insured population in Australia’, Australian Health Review, vol. 42, no. 3, pp. 241-7. 
Harel, Z, Sholzberg, M, Shah, P, Pavenski, K, Harel, S, Wald, R, Bell, C & Perl, J 2014, 
‘Comparisons between novel oral anticoagulants and vitamin K antagonists in patients 
with CKD’, Journal of the American Society of Nephrology, vol. 25, no. 3, pp. 432-42. 
Heine, H, Brandenburg, V & Schrimer, S 2018, ‘Oral anticoagulation in chronic kidney disease 
and atrial fibrillation’, Deutsches Arzteblatt international, vol. 115, no. 17, pp. 287-94. 
Heit, J 2015, ‘Epidemiology of venous thromboembolism’, Nature reviews. Cardiology, vol. 12, 
no. 8, pp. 464-74. 
Hellfritzsch, M, Grove, E, Husted, S, Rasmussen, L, Poulsen, B, Johnsen, S, Hallas, J & 
Pottegård, A 2016, ‘Clinical events preceding switching and discontinuation of oral 
anticoagulant treatment in patients with atrial fibrillation’, EP Europace, vol. 19, no. 7, 
pp. 1091-5. 
Hillis, C & Crowther, M 2014, ‘Acute phase treatment of VTE: Anticoagulation, including non-
vitamin K antagonist oral anticoagulants’, Thromb Haemost, vol. 114, no. 1, p. 210. 
Hinojar, R, Jiménez-Natcher, JJ, Fernández-Golfín, C & Zamorano, JL 2015, ‘New oral 
anticoagulants: a practical guide for physicians’, European Heart Journal - 
Cardiovascular Pharmacotherapy, vol. 1, no. 2, pp. 134-45. 
Thesis | Kerry Watts 
 
Page | 115  
 
International Society of Thromobosis and Haemostasis 2015, New SSC recommendations and 
guidelines released by Journal of Thromosis and Haemostasis, 
https://www.isth.org/news/news.asp?id=252831&hhSearchTerms=%22CRNMB%22. 
Jordan, M 2015, ‘Research study into the intoruduction of a clinical pharmacist into a general 
parctice and an evaluation of the outocmes on the management of oral anticoagulants’. 
Kaatz, S, Ahmad, D, Spyropoulos, A, Schulman, S & Anticoagulation, tSoCo 2015, ‘Definition 
of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation 
and venous thromboembolic disease in non-surgical patients: communication from the 
SSC of the ISTH’, Journal of Thrombosis and Haemostasis, vol. 13, no. 11, pp. 2119-26. 
Kakkos, SK, Kirkilesis, GI & Tsolakis, IA 2014, ‘Efficacy and safety of the new oral 
anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and 
secondary prevention of venous thromboembolism: A systematic review and meta-
analysis of phase III trials’, European Journal of Vascular and Endovascular Surgery, 
vol. 48, no. 5, pp. 565-75. 
Kamien, M 2006, ‘Remove the tooth, but don’t stop the warfarin’, Australian Family Physician, 
vol. 35, no. 4, pp. 233-5. 
Kannel, W & Benjamin, E 2008, ‘Status of the epidemiology of atrial fibrillation’, The Medical 
clinics of North America, vol. 92, no. 1, pp. 17-ix. 
Kaztung, B, Masters, S & Trevor, A 2017, Basic and Clincial Pharmacology, 14 edn, vol. , 
McGraw Hill Medical. 
Kearon, C, Akl, E, Ornelas, J, Blaivas, A, Jimenez, D, Bounameaux, H, Huisman, M, King, C, 
Morris, T, Sood, N, Stevens, S, Vintch, J, Wells, P, Woller, S & Moores, L 2016, 
‘Antithrombotic therapy for vte disease: Chest guideline and expert panel report’, Chest, 
vol. 149, no. 2, pp. 315-52. 
Khan, F & Datta, Y 2015, ‘Risk of bleeding during long-term anticoagulation with warfarin: A 
tertiary care center experience’, Blood Coagul Fibrinolysis, vol. 26, no. 1, pp. 110-2. 
Kocabas, U, Kaya, E & Avcı, G 2016, ‘Novel oral anticoagulants in non-valvular atrial 
fibrillation: Pharmacological properties, clinical trials, guideline recommendations, new 
antidote drugs and real-world data’, International Journal of the Cardiovascular 
Academy, vol. 2, no. 4, pp. 167-73. 
Larsen, T, Skjøth, F, Nielsen, P, Kjældgaard, J & Lip, G 2016, ‘Comparative effectiveness and 
safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial 
fibrillation: propensity weighted nationwide cohort study’, British Medical Journal, vol. 
353, p. i3189. 
Leung, C, Chong, C & Lim, W 2017, ‘Medical student-led patient education prior to hospital 
discharge improves 1-month adherence rates’, Internal Medicine Journal, vol. 47, no. 3, 
pp. 328-32. 
Lip, G, Keshishian, A, Kamble, S, Pan, X, Mardekian, J, Horblyuk, R & Hamilton, M 2016, 
‘Real-world comparison of major bleeding risk among non-valvular atrial fibrillation 
patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin’, Journal of 
Thrombosis and Haemostasis, vol. 116, no. 11, pp. 975-86. 
Lip, GYH, Frison, L, Halperin, JL & Lane, DA 2011, ‘Comparative Validation of a Novel Risk 
Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: 
The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding 
History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) Score’, 
Journal of the American College of Cardiology, vol. 57, no. 2, pp. 173-80. 
López-López, J, Sterne, J, Thom, H, Higgins, J, Hingorani, A, Okoli, G, Davies, P, Bodalia, P, 
Bryden, P, Welton, N, Hollingworth, W, Caldwell, D, Savović, J, Dias, S, Salisbury, C, 
Eaton, D, Stephens-Boal, A & Sofat, R 2017, ‘Oral anticoagulants for prevention of 
Thesis | Kerry Watts 
 
Page | 116  
 
stroke in atrial fibrillation: systematic review, network meta-analysis, and cost 
effectiveness analysis’, British Medical Journal, vol. 359, p. j5058. 
Lutsey, P, Norby, F, Zakai, N, MacLehose, R, Chen, L, Shah, S, Datta, Y & Alonso, A 2019, 
‘Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial 
fibrillation patients’, Curr Med Res Opin, vol. 35, no. 5, pp. 837-45. 
Lutz, J, Jurk, K & Schinzel, H 2017, ‘Direct oral anticoagulants in patients with chronic kidney 
disease: patient selection and special considerations’, International journal of nephrology 
and renovascular disease, vol. 10, pp. 135-43. 
Marsh, D 2018, Severity of adverse drug reactions, 
https://www.merckmanuals.com/home/drugs/adverse-drug-reactions/severity-of-adverse-
drug-reactions. 
McBane, RD & Marshall, A 2017, Direct-Acting Oral Anticoagulants Dos and Dont's, 
medscape, medscape, http://www.medscape.com/viewarticle/879896. 
CE Committee 2017, Non-vitamin K Antagonist Oral Anticoagulant (NOAC) Guidelines, by 
McCaughan, B. 
McIlroy, G, Smith, N, Lokare, A, Beale, K & Kartsios, C 2018, ‘Treatment failure in patients 
receiving direct oral anticoagulants: Clinical management and outcomes from a single-
center review of 59 consecutive patients’, Blood, vol. 132, no. Supplement 1, pp. 5058-. 
Medscape 2016, Coumadin, Medscape, viewed May 2017, <http://www.rxlist.com/coumadin-
drug.htm>. 
Mekaj, Y, Mekaj, A, Duci, S & Miftari, E 2015, ‘New oral anticoagulants: their advantages and 
disadvantages compared with vitamin K antagonists in the prevention and treatment of 
patients with thromboembolic events’, Ther Clin Risk Manag., vol. 11, pp. 967-77. 
Milling, T & Frontera, J 2017, ‘Exploring indications for the Use of direct oral anticoagulants 
and the associated risks of major bleeding’, The American journal of managed care, vol. 
23, no. 4 Suppl, pp. S67-S80. 
MIMS Australia 2016, Warfarin, NSW Health via CIAP. 
Minuk, L, Lazo-Langner, A, Kovacs, J, Robbins, M, Morrow, B & Kovacs, M 2010, ‘Normal 
levels of protein C and protein S tested in the acute phase of a venous thromboembolic 
event are not falsely elevated’, Thrombosis Journal, vol. 8, no. 1, p. 10. 
Monelli, M, Molteni, M, Cassetti, G, Bagnara, L, De Grazia, V, Zingale, L, Zilli, F, Bussotti, M, 
Totaro, P, De Maria, B & Dalla Vecchia, L 2019, ‘Non-vitamin K oral anticoagulant use 
in the elderly: a prospective real-world study - data from the REGIstry of patients on 
Non-vitamin K oral Anticoagulants (REGINA)’, Vascular health and risk management, 
vol. 15, pp. 19-25. 
Morisky, D, Green, L & Levine, D 1986, ‘Concurrent and predictive validity of a self-reported 
measure of medictaion adherence’, Med Care, no. 24, pp. 67-74. 
Murali, P 2019, What's new in SPSS Statistics 26, IBM developer, April 2019, 
https://developer.ibm.com/predictiveanalytics/2019/04/09/whats-new-in-spss-statistics-
26/  
Nelson, W, Desai, S, Damaraju, C, Lu, L, Fields, L, Wildgoose, P & Schein, J 2015, 
‘International normalized ratio stability in warfarin-experienced patients with 
nonvalvular atrial fibrillation.’, American Journal of Cardiovascular Drugs, vol. 15, no. 
3, pp. 205-11. 
Nordstrom, BL, Evans, MA, Murphy, BR, Nutescu, EA, Schein, JR & Bookhart, BK 2015, 
‘Risk of recurrent venous thromboembolism among deep vein thrombosis and pulmonary 
embolism patients treated with warfarin’, Current Medical Research and Opinion, vol. 
31, no. 3, pp. 439-47. 
Northup, PG & Caldwell, SH 2013, ‘Coagulation in liver disease: A guide for the clinician’, 
Clinical Gastroenterology and Hepatology, vol. 11, no. 9, pp. 1064-74. 
Thesis | Kerry Watts 
 
Page | 117  
 
NPS 2013, ‘Apixaban (Eliquis)  for stroke prevention in non-valvular atrial fibrillation ’, viewed 
May 2017, https://www.nps.org.au/radar/articles/apixaban-eliquis-for-stroke-prevention-
in-non-valvular-atrial-fibrillation. 
NSW Government 2018, Illawarra-Shoalhaven, <https://www.nsw.gov.au/improving-
nsw/regional-nsw/our-regions/illawarra-shoalhaven/>. 
Obamiro, K, Chalmers, L & Bereznicki, L 2016, ‘Development and validation of an oral 
anticoagulant knowledge tool’, PLOS  ONE, vol. 11, no. 6. 
Obamiro, K, Chalmers, L, Lee, K, Bereznicki, B & Bereznicki, L 2018, ‘Adherence to oral 
anticoagulants in atrial fibrillation: An australian survey’, Journal of Cardiovascular 
Pharmacology and Therapeutics, vol. 23, no. 4, pp. 337-43. 
Ordi-Ros, J, Sáez-Comet, L, Pérez-Conesa, M, Vidal, X, Riera-Mestre, A, Castro-Salomó, A, 
Cuquet-Pedragosa, J, Ortiz-Santamaria, V, Mauri-Plana, M, Solé, C & Cortés-
Hernández, J 2019, ‘Rivaroxaban versus vitamin k antagonist in antiphospholipid 
syndrome: A randomized noninferiority trial’, Annals of Internal Medicine, vol. 171, no. 
10, pp. 685-94. 
Paige, E, Kemp-Casey, A, Korda, R & Banks, E 2015, ‘Using australian pharmaceutical benefits 
scheme data for pharmacoepidemiological research: Challenges and approaches’, Public 
Health Research and Practice, vol. 25, no. 4. 
Paschke, L, Klimke, K, Altiner, A, von Stillfried, D & Schulz, M 2020, ‘Comparing stroke 
prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients 
with atrial fibrillation: a nationwide retrospective observational study’, BMC Medicine, 
vol. 18, no. 1, p. 254. 
Petrie, A & Sabin, C 2009, Medical statistics at a glance, 3rd edn, Blackwell Publishing. 
Piazza, G, Nguyen, T, Cios, D, Labreche, M, Hohlfelder, B, Fanikos, J, Fiumara, K & 
Goldhaber, S 2011, ‘Anticoagulation-associated adverse drug events’, The American 
journal of medicine, vol. 124, no. 12, pp. 1136-42. 
Rivera-Caravaca, J, Marin, F, Esteve-Pastor, M, Ferreira, I, Badimon, L, Rafols, C, Ruiz-Ortiz, 
M & Anguita, M 2018, ‘Switching to non-vitamin K antagonist oral anticoagulants in 
atrial fibrillation patients taking vitamin K antagonists: a 1-year report of the SULTAN 
registry’, European Heart Journal, vol. 39, no. 1. 
Roberts, G, Chong, C, Quinn, S, Cameron-Collins, S, Forbes, H, Johnason, J, Kitto, L, Marotti, 
S, Nguyen, H, Reid, S, Sullivan, C, Spyrou, N, Wierenga, L & Wisdom, A 2016, ‘The 
impact of novel oral anticoagulant availability on anticoagulant-related hospital 
admission rates’, paper presented to Medicines Management 42nd SHPA National 
Conference, Perth, 16-19 November 2016. 
Roberts, G, Chong, C, Quinn, S, Cameron-Collins, S, Forbes, H, Johnson, J, Kitto, L, Marotti, S, 
Nguyen, H, Reid, S, Sullivan, C, Spyrou, N, Wierenga, L, Wisdom, A & Jacques, A 
2019, ‘Evaluation of the effect of direct oral anticoagulant availability on hospital 
presentations for bleeding related to oral anticoagulation in South Australia’, Journal of 
Pharmacy Practice and Research, vol. 49, no. 6, pp. 517-24. 
Rollins, B, Silva, M, Donovan, J & Kanaan, A 2014, ‘Evaluation of oral anticoagulants for the 
extended treatment of venous thromboembolism using a mixed-treatment comparison, 
meta-analytic approach’, Clinical Therapeutics, vol. 36, no. 10, pp. 1454-64.e3. 
Rolls, C, Obamiro, K, Chalmers, L & Bereznicki, B 2016, ‘The relationship between knowledge, 
health literacy and adherence among patients taking oral anticoagulants for stroke 
thromboprophylaxis in atrial fibrillation’, PLOS  ONE. 
Runciman, W, Roughead, E, Semple, S & Adams, R 2003, ‘Adverse drug events and medication 
errors in Australia’, International journal for quality in health care : journal of the 
International Society for Quality in Health Care, vol. 15 Suppl 1, pp. i49-59. 
Thesis | Kerry Watts 
 
Page | 118  
 
Sardar, P, Chatterjee, S, Herzog, E, Pekler, G, Mushiyev, S, Pastori, LJ, Visco, F & Aronow, 
WS 2015, ‘New oral anticoagulants in patients with cancer: current state of evidence’, 
Am J Ther, vol. 22, no. 6, pp. 460-8. 
Saunders, M, Lewis, P & Thornhill, A 2012, Research methods for business students, 6th edn, 
Pearson Education Limited. 
Scholefield, A & Wilcken, H 2017, ‘One-third of patients skip DOACs within six months’, 






Scott, S 2017, Blood-thinners Xarelto, Eliquis and Pradaxa marketed to doctors as drug 
companies splash cash, ABC News, Online, 12 Feb 2017, 4:57pm, 
http://www.abc.net.au/news/2017-02-12/prescriptions-for-new-blood-thinning-drugs-
skyrocket/8250856. 
Sembill, J, Kuramatsu, J, Schwab, S & Huttner, H 2019, ‘Resumption of oral anticoagulation 
after spontaneous intracerebral hemorrhage’, Neurological Research and Practice, vol. 1, 
no. 1, p. 12. 
Sennesael, A, Larock, A, Devalet, B, Mathieux, V, Verschuren, F, Muschart, X, Dalleur, O, 
Dogné, J & Spinewine, A 2018, ‘Preventability of serious thromboembolic and bleeding 
events related to the use of oral anticoagulants: a prospective study’, British Journal of 
Clinical Pharmacology, vol. 84, no. 7, pp. 1544-56. 
Shehab, A, Bhagavathula, A, Abebe, T, Abegaz, T, Elnour, A, Sabbour, H, Uzzafer, M, Hersi, A 
& Hamad, A 2019, ‘Patient adherence to novel oral anticoagulants (noacs) for the 
treatment of atrial fibrillation and occurrence of associated bleeding events: A systematic 
review and meta-analysis’, Curr Vasc Pharmacol, vol. 17, no. 4, pp. 341-9. 
Shikdar, S & Bhattacharya, P 2019, International Normalized Ratio (INR), StatPearls 
Publishing, Treasure Island (FL). 
Shpak, M, Ramakrishnan, A, Nadasdy, Z, Cowperthwaite, M & Fanale, C 2018, ‘Higher 
incidence of ischemic stroke in patients taking novel oral anticoagulants’, Stroke, vol. 49, 
no. 12, pp. 2851-6. 
Signorelli, F, Nogueira, F, Domingues, V, Mariz, H & Levy, R 2016, ‘Thrombotic events in 
patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight 
cases’, Clinical Rheumatology, vol. 35, no. 3, pp. 801-5. 
Simper, G, Celik, A, Kunze-Schumacher, H, Blasczyk, R & Bade-Döding, C 2017, ‘Physiology 
and pathology of drug hypersensitivity: Role of human leukocyte antigens’, in. 
Skelley, JW, White, CW & Thomason, AR 2017, ‘The use of direct oral anticoagulants in 
inherited thrombophilia’, Journal of Thrombosis and Thrombolysis, vol. 43, no. 1, pp. 
24-30. 
Smet, L, Heggermont, W, Goossens, E, Eeckloo, K, Vander Stichele, R, De Potter, T & De 
Backer, T 2018, ‘Adherence, knowledge, and perception about oral anticoagulants in 
patients with atrial fibrillation at high risk for thromboembolic events after 
radiofrequency ablation’, J Adv Nurs, vol. 74, no. 11, pp. 2577-87. 
Smith, W 2013, ‘adverse drug reactions allergy? side-effect? intolerance?’, Australian Family 
Physician, vol. 42, pp. 12-6. 
Snyder, R & Fields, W 2010, ‘A model for medication safety event detection’, International 
journal for quality in health care : journal of the International Society for Quality in 
Health Care, vol. 22, no. 3, pp. 179-86. 
Thesis | Kerry Watts 
 
Page | 119  
 
Stevens, H, Tran, H & Gibbs, H 2019, ‘Venous thromboembolism:  current management’, 
Australian Prescriber, vol. 42, no. 4, pp. 123-6. 
Streiff, MB, Agnelli, G, Connors, JM, Crowther, M, Eichinger, S, Lopes, R, McBane, RD, Moll, 
S & Ansell, J 2016, ‘Guidance for the treatment of deep vein thrombosis and pulmonary 
embolism’, J Thromb Thrombolysis, vol. 41, pp. 32-67. 
Sultana, J, Cutroneo, P & Trifirò, G 2013, ‘Clinical and economic burden of adverse drug 
reactions’, Journal of pharmacology & pharmacotherapeutics, vol. 4, no. Suppl 1, pp. 
S73-S7. 
Tadros, R & Shakib, S 2010, ‘Warfarin Indications, risks and drug interactions’, Australian 
Family Physician, vol. 39, pp. 476-9. 
Tariq, S & Woodman, J 2013, ‘Using mixed methods in health research’, JRSM Short Reports, 
vol. 4, no. 6, p. 2042533313479197. 
TGA 2017, Database for adverse events notifications- Rivaroxaban, Australian Government. 
Thachil, J 2012, ‘Recurrent venous thromboembolism while on anticoagulant therapy’, Blood 
Reviews, vol. 26, no. 4, pp. 175-81. 
Toth, P 2016, ‘Considerations for long-term anticoagulant therapy in patients with venous 
thromboembolism in the novel oral anticoagulant era’, Vasc Health Risk Manag, vol. 12, 
pp. 23-34. 
Tran, H, Gibbs, H, Merriman, E, Curnow, J, Young, L, Bennett, A, Chee Wee, T, Chunilal, S, 
Ward, C, Baker, R & Nandurkar, H 2019, ‘New guidelines from the Thrombosis and 
Haemostasis Society of Australia and New Zealand for the diagnosis and management of 
venous thromboembolism’, Medical Journal Australia. 
Tung, J, Mamdani, M, Juurlink, D, Paterson, J, Kapral, M & Gomes, T 2015, ‘Rates of ischemic 
stroke during warfarin treatment for atrial fibrillation’, Stroke, vol. 46, no. 4, pp. 1120-2. 
U.S. Department of Health and Health Services 2020, Adverse drug events, 
<https://health.gov/our-work/health-care-quality/adverse-drug-events>. 
University of Wollongong 2019, What is IHIP?, <https://ahsri.uow.edu.au/chrisp/what-is-
ihip/index.html>. 
Van Es, N, Coppens, M, Schulman, S, Middeldorp, S & Buller, H 2014, ‘Direct oral 
anticoagulants compared with vitamin K antagonists for acute venous thromboembolism 
evidence from phase 3 trials’, Blood, vol. 124, no. 12, pp. 1968-75. 
Vandiver, J, Faulkner, D, Erlandson, M & Onysko, M 2014, ‘Is a novel anticoagulant  right for 
your patient?’, The Journal of Family Practice, vol. 63, no. 1, pp. 22-8. 
Vinogradova, Y, Coupland, C, Hill, T & Hippisley-Cox, J 2018, ‘Risks and benefits of direct 
oral anticoagulants versus warfarin in a real world setting: cohort study in primary care’, 
British Medical Journal, vol. 362, no. k2505. 
Viprey, M, Jeannin, R, Piriou, V, Chevalier, P, Michel, C, Aulagner, G, Berthiller, J & Armoiry, 
X 2017, ‘Prevalence of drug-related problems associated with direct oral anticoagulants 
in hospitalized patients: a multicenter, cross-sectional study’, Journal of Clinical 
Pharmacy and Therapeutics, vol. 42, no. 1, pp. 58-63. 
Vutukuri, J, Shanahan, C, Kippist, C & Fardell, B 2015, ‘Pharmacist  intervention: Putting the 
do in 'DOAC'’, paper presented to Medicines Managament 2015, Melbourne, 3rd 
December 2015. 
Watts, K 2017, ‘Rivaroxaban versus warfarin: VTE treatment failure- A pilot study’, paper 
presented to PSA17, Sydney. 
Weatherspoon, D & Chattopadhyay, A 2013, ‘International Classification of Diseases Codes and 
their Use in Dentistry’, Journal of dental, oral and craniofacial epidemiology, vol. 1, no. 
4, pp. 20-6. 
Thesis | Kerry Watts 
 
Page | 120  
 
Weber, J, Olyaei, A & Shatzel, J 2019, ‘The efficacy and safety of direct oral anticoagulants in 
patients with chronic renal insufficiency: A review of the literature’, European Journal 
of Haematology, vol. 102, no. 4, pp. 312-8. 
Woo, S, Cragg, A, Wickham, M, Villanyi, D, Scheuermeyer, F, Hau, J & Hohl, C 2020, 
‘Preventable adverse drug events: Descriptive epidemiology’, British Journal of Clinical 
Pharmacology, vol. 86, no. 2, pp. 291-302. 
Yao, X, Abraham, N, Sangaralingham, L, Bellolio, M, McBane, R, Shah, N & Noseworthy, P 
2016, ‘Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin 
in nonvalvular atrial fibrillation’, Journal of the American Heart Association, vol. 5, no. 
6. 
Zhang, H, Du, W, Gnjidic, D, Chong, S & Glasgow, N 2019, ‘Trends in adverse drug reaction-
related hospitalisations over 13 years in New South Wales, Australia’, Internal Medicine 
Journal, vol. 49, no. 1, pp. 84-93. 
 
  
Thesis | Kerry Watts 
 
















Thesis | Kerry Watts 
 





Thesis | Kerry Watts 
 












Thesis | Kerry Watts 
 
Page | 124  
 
APPENDIX 3 
Interview Guide- Vascular Outpatient Clinic Cohort 
 
Before turning on recorder 
Hello, my name is Kerry Watts I am a pharmacist from the Wollongong Hospital 
Pharmacy Department and am currently undertaking a Masters of Philosophy degree at 
the University of Wollongong. I understand you had indicated you would be happy to be 
interviewed about your medications used to treat and help prevent blood clots.  
 
Are you happy to proceed? 
 
Turn on recorder 
The interview will take place in two parts. The first part is to collect some information 
about yourself and the completion of the Morisky Medication Adherence Tool, which 
requires yes/no answers relating to how you take your medications. The second part of 
the interview, will be more about the safe use of your medicines. 
 
Part 1: 
The following questions I am going to ask you are about yourself, these results will be 
de-identified 
 
Sex: M   F 
Year of Birth: 
 
1: Please tell me why you came into the vascular outpatient clinic? 
 
Prompts 
Bleed, VTE  
Is this the first time this has happened? 
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 General Questions Answers 
1 What is the name of your anticoagulant medicine? 
Prompts 
Oral anticoagulants: Eliquis, Xarelto, Aspirin, Clopidogrel 
 
2 Why has your doctor prescribed this medicine?  
3 How does the medicine work in the body?  
4 How many times a day do you need to take this medicine? 
Prompts  
            everyday…? how about in the past week? 
Prompts 
time of the day -morning, midday, evening, before bed 
With food? Without food? With water or any other juices? 
 
5 For how long do you need to take this medicine (3, 6 
months, life-long)? 
 
6 Why is it important to take this medicine exactly as your 
doctor has told you? 
 
7 Is it acceptable to take this medicine at different times as 
long as you take it on the required days? 
 
8 Is it acceptable to double the next dose of this medicine if 
you miss a dose? 
 
9 Is it possible that skipping one dose of this medicine could 
worsen your condition? 
 
10 Is it appropriate to stop taking this medicine once you feel 
better? 
 
11 Is it safe to take anti-inflammatory medicines like ibuprofen 
while you are taking this medicine? 
 
12 Is it safe to take vitamin supplements and herbal medicines 
with this medicine without consulting your doctor? 
 
13 Is there any benefit in taking more of this medicine that your 
doctor has told you to take? 
 
14 Will drinking too much alcohol increase the risk of side 
effects with this medicine? 
 
15 Is it necessary to inform a surgeon, dentist or other health 
professional that you are taking this medicine before 
undergoing a procedure? 
 
16 Is it important that all the health care practitioners you see 
know you are that you are taking this medicine? 
 
17 What is the most important side effect of this medicine?  
18 Three signs of side effects that you should watch out for 
while taking this medicine are: 
 
19 Three things you can do to reduce your risk to side effect 
are: 
 
20 What is the best step to take if you accidentally take too 
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4: I am now going to ask you some questions that require one-word answers, 
relating to the way you take your ……. (answer to question 2): 
 
Do you ever forget to take your ……. (answer to question 2)? No=1, Yes=0 
Are you careless at times about taking your ……. (answer to 
question 2)? 
No=1, Yes=0 
When you feel better do you sometimes stop taking your ……. 
(answer to question 2)  
No=1, Yes=0 
Sometimes if you feel worse when your ……. (answer to 
question 2), do you stop taking it? 
No=1, Yes=0 
Score: high-low; yes=0; no=1. Range 0-4. 1=low adherence; 2-3=medium 
adherence; 4=high adherence 
Self-reported medication-taking scale, Morisky, Green & Levine Medication Adherence Tool 
 
Now we will commence on the second part of the interview questions. 
Part 2: 
5a: Please tell me about any of your other medical conditions that you regularly need to 
see a doctor for? 
Prompt 
GP, Specialists- Heart specialist, kidney specialist, liver specialist 
 
5b: Please tell me the names of any other medications you may take and what you take 
them for? 
 
6: Please tell me if you have made any recent changes to your lifestyle behaviours, such 
as changes to your diet, exercise, alcohol intake and/or physical activity? 
  
7: Please tell me about any changes have you had to your medications recently?  
Prompt 
especially in the last month? 
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 PARTICIPANT INFORMATION SHEET- Vascular  
 Outpatient Clinic Cohort 
 
TITLE: Investigating the safe use of medications to treat and help prevent blood clots 
PURPOSE OF THE RESEARCH 
This is an invitation to participate in a study being conducted by Kerry Watts, a 
Wollongong Hospital pharmacist, who is undertaking her Masters of Philosophy 
Research degree under the supervision of A/Prof Judy Mullan, Margaret Jordan, Dr 
Luise Lago and Dr Laurencia Villalba. The purpose of this study is to investigate the 
safe use of medications used to treat and prevent blood clots. 
 
This project is important because taking these medications as prescribed by the doctor 
is important to making sure they work correctly. The information from this study will be 
used to identify ways to help ensure that these medications are taken safely and 
appropriately.    
INVESTIGATORS  
 
Kerry Watts A/Prof Judy Mullan Margaret Jordan 





Wollongong Hospital Pharmacy 
Department 
Kerry.watts1@health.nsw.gov.au  jmullan@uow.edu.au 
 
Margaret.jordan@health.nsw.gov.au  
4222 5449 4221 5980 4255 1531 
Dr Laurencia Villalba Dr Luise Lago 
Wollongong Hospital Vascular 
Department 
CHRISP 
laurenciavillalba@live.com lago@uow.edu.au  
 
METHOD AND DEMANDS ON PARTICIPANTS  
If you choose to be included in this study, you will be asked to take part in an individual 30-
minute interview conducted by Kerry Watts over the phone at a time which is convenient to 
you. The interview questions have been designed to learn more about what you know and 
how you take your medications to prevent and/or treat blood clots. 
The interview will be recorded for later transcription and analysis. Your medical records 
from the vascular outpatient clinic will be reviewed as part of the study to learn more about 
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the management of your blood clot(s). All data will not include your name to maintain your 
confidentiality. Please note that you will not be paid for your interview session. 
POSSIBLE RISKS, INCONVENIENCES AND DISCOMFORTS 
Apart from the time to attend the interview we can foresee no risks for you. However, if 
participation in this study causes you any distress please seek further advice from your 
doctor. Your involvement in the study is voluntary and you may withdraw your participation 
from the study at any time.  However, once the information has been collected you will not 
be able to withdraw your contribution because no names will be included in the transcripts 
and the analysis. Not participating in the study will not affect your relationship with the 
University of Wollongong or Illawarra Shoalhaven Local Health District. 
BENEFITS OF THE RESEARCH 
The results of the study will be used to help pharmacists and other healthcare workers 
understand how to best educate patients on their medications for the treatment and 
prevention of blood clots and reduce medication related problems. Findings from the study 
will be published in a thesis, in academic journals and as conference presentations. A copy 
of the study conclusions will be available to any interested person by contacting the 
investigators. Please note that individuals will not be identified in any reports or publications 
arising from this research.  
ETHICS REVIEW AND COMPLAINTS 
This study has been reviewed by the Human Research Ethics Committee of the University 
of Wollongong. 
If you have any concerns or complaints regarding the way this research has been 
conducted, you can contact the UOW Ethics Officer on (02) 4221 3386 or email:  rso-
ethics@uow.edu.au  
Thank you for your interest in this study. If you would like further information about this 
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APPENDIX 5 
                                                  
 
 
CONSENT FORM for individual interviews 
 




Kerry Watts Associate Professor 
Judy Mullan 
















4222 5449 4221 5980 4255 1531 4221 5835 







I have been given information about the project “Investigating the safe use of 
medications to treat and help prevent blood clots” and I have discussed the research 
with one of the investigators. 
I have been advised of any possible risks or burdens associated with this research and have 
had the opportunity to ask an investigator any questions about my participation. 
I understand that my participation is voluntary, I will not receive any payment and that my 
interview responses will be recorded. I know that I am free to refuse to participate and that I 
can withdraw from the research at any time without affecting my relationship with the 
University of Wollongong or the Illawarra Shoalhaven Local Health District. 
If I have any questions about the research, I can contact Kerry Watts at the Wollongong 
Hospital Pharmacy Department on 4222 5449 or email Kerry.watts1@health.nsw.gov.au or if I 
have any concerns or complaints regarding the way the research is being conducted, I can 
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contact the Ethics Officer, Human Research Ethics Committee, Office of Research, University 
of Wollongong on 4221 3386 or email:  rso-ethics@uow.edu.au  
By signing below, I am giving my consent to participate in this research project by taking part 
in an interview which will be recorded and give permission for the researchers to review my 
medical records. I also give my consent for the results of the study to be written as part of a 
thesis, as well as in journal publications and as conference presentations. 
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APPENDIX 8 
Table 29- Comparison between PBS data apixaban, rivaroxaban and warfarin- raw data 
2015- 2017 PBS oral anticoagulant prescriptions (persons) 
 Apixaban Rivaroxaban Warfarin 
 N (%) N (%) N (%) 
SEX       
   Male  1872 (53.3) 2960 (52.4) 3556 (54.2) 
   Female 1643 (46.7) 2688 (47.6) 3003 (47.6) 
   Total  3515 (100.0) 5648 (100.0) 6559 (100.0) 
AGE       
   <65 638 (18.2) 1616 (28.6) 813 (12.4) 
   65-69 462 (13.1) 780 (13.8) 646 (9.8) 
   70-74 579 (16.5) 949 (16.8) 966 (14.7) 
   75-79 627 (17.8) 933 (16.5) 1227 (18.7) 
   80-84 612 (17.4) 756 (13.4) 1348 (20.6) 
   85+ 597 (17.0) 614 (10.9) 1559 (23.8) 
REGION       
   Illawarra 2706 (77.0) 3857 (68.3) 4587 (69.9) 
   Shoalhaven 809 (23.0) 1791 (31.7) 1972 (30.1) 
TOTAL 3515 (100.0) 5648 100.0 6559 (100.0) 
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Table 30- Haemorrhage by oral anticoagulant- raw data 
2015- 2017 Apixaban Rivaroxaban Warfarin Total Rate2 
 N (%) N  (%) N  (%) N (%)  
TYPE OF BLEED          
   Cerebrovascular  ˟ ˟ ˟ ˟ 20 (9.0) 26 (6.1) 0.9 
   Epistaxis ˟ ˟ ˟ ˟ 29 (13.1) 42 (9.9) 1.4 
   GI 
(haematemesis, 
melaena, rectal) 
20 (38.5) 82 (53.6) 104 (47.1) 205 (48.3) 7.0 
   Haematoma ˟ ˟ ˟ ˟ 12 (5.4) 15 (3.5) 0.5 
   Haematuria 11 (21.2) 20 (13.2) 24 (10.8) 55 (3.0) 1.9 
   Haemoptysis ˟ ˟ ˟ ˟ 13 (5.4) 21 (4.9) 0.7 
   Mouth ˟ ˟ 13 (8.6) ˟ ˟ 20 (4.7) 0.7 
   Other (PV) 7 (13.5) 17 (11.3) 16 (7.2) 40 (9.4) 1.4 
   Bleeds Total 52 (100.0) 151 (100.0) 222 (100.0) 425 (100.0) 14.5 
Rate1 7.4  13.3  16.9     
MAJOR BLEED          
   Intracranial ˟ ˟ ˟ ˟ 20 (9.0) 26 (6.1)  
   GI ˟ ˟ ˟ ˟ 34 (15.3) 55 (13.0)  
   Other  5 (9.6) 9 (6.0) 13 (5.9) 27 (6.4)  
Major bleed total 12 (23.1) 29 (19.4) 67 (30.2) 108 (24.5) 3.7 
Rate1 1.7  2.6  5.1     
CRNMB           
CRNMB total 40 (76.9) 121 (80.6) 155 (69.8) 316 (74.5) 10.8 
Rate1 5.7  10.7  11.8     
˟ suppressed cells <5 or to maintain confidentiality 
1. Rates per 1,000 persons per year from persons taking individual oral anticoagulant (apixaban n=3515, 
rivaroxaban n=5648, warfarin n=6559)/2 
2. Rates per 1,000 persons per year per population; total persons taking oral anticoagulants (n=14577 patients 
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APPENDIX 10 
Table 31- Stroke ADE by oral anticoagulant- raw data 
2015-2017 Apixaban Rivaroxaban Warfarin Total 
 N (%) N (%) N (%) N (%) 
Stroke         
   haemorrhagic 3 (16.7) 3 (10.7) 20 (25.3) 26 (20.8) 
   ischaemic 15 (83.3) 25 (89.3) 59 (79.7) 99 (79.2) 
Total  18 (100.0) 28 (100.0) 79 (100.0) 125 (100.0) 
Rate1 2.6 - 2.5 - 6.0 - 4.3 - 
1. Rates per 1,000 persons per year from persons taking individual oral anticoagulant (apixaban n=3515, 
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APPENDIX 11 
Table 32- Pairwise comparison of admitted cohort comorbidities by oral anticoagulant, 
2015/16-2016/17  






Comorbidity χ2 (p) χ2 (p) χ2 (p) 
   Cardiac (CF, IHD) 7.200 (P= 0.0073)* 2.226 (P= 0.1357) 3.585 (P= 0.0583) 
   HTN 9.163 (P= 0.0025)* 11.710 (P=0.0006)* 0.116 (P= 0.7333) 
   DM 4.125 (P= 0.0423)* 1.586 (P= 0.2080) 1.537 (P= 0.2151) 
Hyperlipid/cholesterol 0.016 (P= 0.9002) 0.044 (P= 0.8341) 0.011 (P= 0.9161) 
   Stroke (CVA, TIA) 12.542 (P=0.0004)* 1.540 (P= 0.2146) 10.211 (P= 0.0014)* 
   PVD 0.446 (P= 0.5043) 0.995 (P= 0.3185) 5.209 (P= 0.0225)* 
   Bleeds/Anaemia 0.403 (P= 0.5257) 2.085 (P= 0.1487) 0.975 (P= 0.3234) 
   Thrombophilia ˟ ˟ ˟ 
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When prescribed for AF, rivaroxaban resulted in the least number of stroke ADEs, defined as 
treatment failure, 19.4% compared to warfarin 23.9% and apixaban 23.7%. In contrast however, 
individuals prescribed rivaroxaban for VTE treatment or prophylaxis experienced the highest 
percentage of VTE events, defined as treatment failure, 43.1% (n=28/65) compared with VTE 
failures of 17.0% with warfarin (n=9/53). Based on vascular consultant advice, individuals 
taking rivaroxaban experienced a clinically significant (>0.5) higher rate of treatment failure 6.4 
per 1,000/year compared to 5.6 per 1,000/year taking warfarin.  
 
 
 apixaban rivaroxaban NOACs warfarin 
Indication AF/stroke 59 124 183 222 
   Outcome stroke 14 24 38 53 
   Failure % 23.7 19.4 20.8 23.9 
Indication VTE/post-op prophylaxis ˟ 65 ˟ 53 
   Outcome VTE ˟ 28 ˟ 9 
   Failure % ˟ 43.1 ˟  17.0 
Total failure rate per 1,000/year ab ˟  6.4 ˟  5.6 
a. The yearly rate is the average of the rates from 15/16 and 16/17 (apixaban n=2582, rivaroxaban n=4090, 
NOACs n=6582, warfarin n=5545, total n=11,715) 
b. Counts of persons prescribed each oral anticoagulant do not add to the total counts for all oral 
anticoagulants due to some people prescribed more than one oral anticoagulant during the 2-year study 
period.  
˟ suppressed cells <5 or to maintain confidentiality 
 
Figure 17- Treatment failure by oral anticoagulant, 2015/16-2016/17 
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